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O-linked β-N-acetylglucosamine is a regulatory post translational 
modification. This modification occurs on nearly all functional classes of proteins, 
in the nucleus and cytoplasm. O-GlcNAc is added to serine or threonine by O-
GlcNAc transferase and removed by O-GlcNAcase. Previous attempts to study 
O-GlcNAc-modified proteins have resulted in low yields, making 3-dimensional 
structure determination impossible. In this dissertation O-GlcNAc transferase will 
be co-expressed with domains of human cAMP responsive element-binding 
protein (CREB1) and Abelson tyrosine-kinase 2 (ABL2) in E. coli, to produce O-
GlcNAc-modified protein. The O-GlcNAc-modified protein was expressed in a 
variety of E. coli cell lines at a variety of conditions, but only small quantities of 
insoluble protein were produced. A glycosidase was suspected due to the 
disappearance of the O-GlcNAc modification from the protein. O-(2-acetamido-2-
dexoy-dglucopyranosylidene) amino-N-phenylcarbamate (PUGNAc), a β-N-
acetylglucosaminidase inhibitor, was added to the culture media and increased 
the production of O-GlcNAc-modified protein. This was the first evidence that β-
N-acetylglucosaminidase (NagZ), an E. coli enzyme, cleaves O-GlcNAc from 
proteins in vivo. NagZ was isolated and  shown  to  cleave  O-GlcNAc  from  a  
synthetic  O-GlcNAc-peptide  in  vitro. In E. coli, NagZ cleaves the GlcNAc-β1,4-
N-acetylmuramic  acid  linkage  to  recycle  peptidoglycan in the cytoplasm. A 
NagZ knockout showed no activity towards the O-GlcNAc-peptide, confirming 
NagZ as the enzyme responsible for cleaving O-GlcNAc from our glycoprotein 
expressed in vivo. O-GlcNAc-modified protein produced by the NagZ knockout 
(∆NagZ) co-expression system is highly glycosylated and can be resolubilized 
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from the pellet. The ∆NagZ is a step closer to production of milligram quantities 
of O-GlcNAc-modified protein for structure determination.  
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Chapter 1:  Background 
1. 1 Proteins 
Proteins are macromolecules that are present in all living systems. They which 
play essential roles in many cellular processes such as transport, storage, cellular 
signaling and immune response [1]. A major class of proteins, known as enzymes, act 
as catalyst for many chemical reactions in biological systems. They are composed of 20 
amino acid building blocks. These amino acids, containing a carboxyl end, amino end 
and side chain, are linked together when a dehydration reaction occurs between two 
amino acids and forms a peptide bond (Figure 1-1).  
 
Figure 1-1 Synthesis and structure of the peptide backbone. http://www. 
molecularsciences. org/book/export/html/253 
Proteins are synthesized through two processes called transcription and 
translation. During transcription, RNA polymerase transcribes single strands of DNA into 
complimentary strands of RNA called messenger RNA (mRNA). The mRNA is then 
translated into a polypeptide chain by ribosomes, composed of ribosomal proteins, 
 1 
ribosomal RNA (rRNA), and transfer RNA (tRNA). tRNA is unlike mRNA in that it carries 
amino acids. One side of tRNA has nucleotide base pairs and the other has the amino 
acids that correspond to the nucleotide base pairs. The ribosome synthesizes a protein 
by reading mRNA, binding the appropriate tRNA, and creating peptide bonds between 
each amino acid (Figure1-2) [2].  
 
Figure 1-2 Transcription and translation of proteins. http://www. tokresource. 
org/tok_classes/biobiobio/biomenu/transcription_translation/ 
1. 2 Protein Structure 
The overall 3-dimensional (3D) structure or tertiary structure of a protein is 
dependent upon its primary and secondary structure. The primary structure of a protein 
is its amino acid sequence. The secondary structure describes how this chain of amino 
acids behave in relation to their bond neighbor. Secondary structure consists of alpha 
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helices, beta sheets and non-structured regions called loops. Alpha helices form a 
spiral-like shape with 3. 6 amino acids for every turn. The protein backbone forms the 
inside of the coil with the amino acid side chains at the exterior. The spiral or coil shape 
is stabilized by intramolecular hydrogen bonds formed between the amide group 
hydrogen and the oxygen of a carboxyl group 4 residues away (Figure 1-3). Beta sheets 
are flat or linear in shape and are also held together by hydrogen bonds. These bonds 
differ from those in the alpha helix in that they occur between separate chains. Also, the 
intramolecular hydrogen bond is between the hydrogen of an amide on one chain and 
the oxygen of a carboxyl of a neighboring chain. The alpha helices, beta sheet and 
loops fold to make subunits of the proteins. These subunits describe a protein’s 3D 
tertiary structure. Finally, these tertiary structures of protein monomers fit together to 
make protein complexes or multimers. The structures resulting from these multimers is 
quaternary structure, which is the overall folded state of the entire complex (Figure1-3). 
The tertiary and quaternary structures are held together by hydrogen bonds, ionic 






Figure 1-3  Protein structure. https://www. mun. ca/biology/scarr/iGen3_06-04. html 
1. 3 Protein function as it relates to structure 
Protein function depends on protein structure. In most cases, proteins have to be 
folded in a certain conformation to carry out their function. For example, in lock and key 
ligand binding, enzymes show specificity for substrates by forming an active cite based 
on the enzyme’s structure. This substrate binding event is often part of a cascade of 
events required for function to take place [3].  
1. 4 Post translational modifications 
A post translation modification (PTM) is a covalent chemical modification that 
occurs after the protein has been translated. There are many types of PTMs, such as 
methylation, ubiquitination, phosphorylation, and glycosylation. Methylation adds a 
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methyl group to a lysine or arginine. Ubiquitination is the addition of an entire ubiquitin 
protein molecule to a lysine residue. Phosphorylation and glycosylation are the two 
most common PTMs. Phosphorylation is the addition of a phosphate at a serine and/or 
threonine residue. Glycosylation can be N-linked and O-linked. N-linked glycosylation 
normally consists of the addition of a polysaccharide chain at an asparagine, as long as 
the asparagine is part of a tri-peptide motif consisting of the asparagine, any amino acid 
and then a serine or threonine (N, X, S/T). This consensus sequence is a tri-peptide 
within the sequence of the protein where the N-linked glycosylation may occur. 
Knowledge of this consensus sequence allows us to predict possible glycosylation sites. 
Most O-linked glycosylations are similar to N-linked glycosylations, in that they are long 
chain polysaccharides. The exception is O-linked N-acetylglucosamine (O-GlcNAc), 
which is the addition of a monosaccharide instead of a polysaccharide [4].  
1. 5 O-GlcNAc in the hexosamine biosynthesis pathway 
The hexosamine biosynthesis pathway (HBP) is a metabolic pathway that 
produces uridine diphosphate N-acetylglucosamine (UDP-GlcNAc), the substrate for O-
GlcNAcylation, and other nucleotide hexosamines (Figure 1-4). Hexosamines, also 
called amino sugars, are sugars that have an amino group (-NH2) in place of a hydroxyl 
group. The HBP varies based on the organism. In humans, glucose enters the cell and 
is phosphorylated by hexokinase. Only 2-5% of glucose that enters the cell enters the 
HBP, therefore the level of O-GlcNAcylation is dependent on nutrient availability [5]. 
Once glucose is phosphorylated and converted to fructose-6-phosphate, it can enter the 
HBP or the main glycolytic/glycogen pathway. The HBP is initiated by 
glutamine/fructose aminotransferase (GFAT). GFAT is an enzyme that transfers an 
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amino group to fructose-6-phophate from the amino acid glutamine, producing 
glucosamine-6-phosphate [6]. It is important to add that glucosamine-6-phophate can 
also be produced by glucosamine that enters the cell and is phosphorylated by 
hexokinase [7]. EMeg32, a glucosamine-6-phospate N-acetyltransferase, in an enzyme 
that acetylates glucosamine-6-phosphate using acetyl-CoA as a substrate [8]. N-
acetylglucosamine-6-phosphate, produced by the acetylation reaction, is interconverted 
to N-acetylglucosamine-1-phosphate by N-acetyl phospho-glucosamine mutase 
(AGM1). N-acetylglucosamine-1-phosphate is finally uridylated to UDP-GlcNAc by UDP-
GlcNAc pyrophosphorylase (UAP1) [9].  
1. 6 O-GlcNAc is not your typical glycosylation 
 O-GlcNAc is an O-linked glycosylation that occurs at a serine or a threonine. O-GlcNAc 
is cycled on and off of protein substrates by enzymes. It is added by the enzyme O-
GlcNAc transferase (OGT) and remove by O-GlcNAcase (OGA) (Figure 1-5) [10]. This 
O-linked modification is unlike most glycosylation. Only one sugar is added, as opposed 
to a longer polysaccharide chain. There is no consensus sequence recognized by OGT, 
which makes O-GlcNAc-site prediction difficult [11]. O-GlcNAc has a reciprocal 
relationship with phosphorylation. They can occur on the same protein at the same time 
or at a specific residue interchangeably [12]. This relationship with phosphorylation is 
used by most prediction algorithms to identify possible O-GlcNAc modification sites [12]. 
In mammals, most protein glycosylation occurs in the extracellular matrix or the 






Figure 1-4 The HBP pathway in humans. Yuzwa, S. A. and D. J. Vocadlo, O-glcnac and 
neurodegeneration: Biochemical mechanisms and potential roles in alzheimer's disease 
and beyond. Chemical Society Reviews, 2014. 43(19): p. 6839-6858.  
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Figure 1- 5 Enzymatic cycling of O-GlcNAc by OGT and OGA. Hart, G. W. , M. P. 
Housley, and C. Slawson, Cycling of o-linked beta-n-acetylglucosamine on 
nucleocytoplasmic proteins. Nature, 2007. 446(7139): p. 1017-22.  
1. 7 O-GlcNAc is a regulatory enzyme that is implicated in disease when it is 
dysregulated 
The O-GlcNAc modification was first discovered by Gerald Hart in 1984 and is 
dynamic and regulatory in nature [13]. O-GlcNAc-modified proteins regulate many 
biological processes, such as transcription, translation, protein degradation, cell 
signaling, cell trafficking, apoptosis and cell cycle control [14]. It also regulates some 
physiological events, such as the circadian rhythm, memory formation, and learning 
[15]. When the OGT gene is knocked out in mice, it is embryonic lethal, therefore this 
regulatory modification is essential for life [16].  
Cyclic AMP-response element binding protein 1 (CREB1) is a transcription factor 
that binds to TATA-associated factor (TafII130), a coactivator, to induce transcription of 
the cyclic AMP response element (CRE) gene [17]. When O-GlcNAc is bound to 
CREB1, association with TafII130 is inhibited and transcription is repressed [17]. 
Repression of the CRE gene leads to reduced growth in axons and dendrites in mice 
brain cells [18]. Axon and dendrite growth and connection is how memories are formed. 
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Dysregulated O-GlcNAcylation of CREB1 leads to memory loss in mice and has been 
linked to Alzheimer’s disease [20].  
In the brain, neurons (brain cells) consist of a cell body, dendrites, and axons. 
The neuronal cell body is very similar to other cells and contains the nucleus, cytoplasm 
and cellular membrane. Dendrites carry information into the cell body through electric 
signals, while axons take information away from the cell body. Dendrites are connected 
to the cell body at one end while the axons are at the opposite end of the cell body [21]. 
Microtubules are the major structural component of axons. They play a key role in 
intracellular transport by carrying nutrients and other cellular cargo [21]. They are hollow 
and tubular in shape and are composed of polar filamentous polymers of α/β tubulin 
heterodimers. These microtubules are held together by MT binding proteins such as 
tau. Hyperphosphorylated tau separates tau from the microtubules, causing them to fall 
apart [22]. The hyperphosphorylated tau molecules aggregate within the neuron, 
causing tangles, inhibiting neurotransmission and destroying the cell [23]. The O-
GlcNAc modification can compete with phosphorylation sites on tau. When OGA is 
inhibited in rodents, the O-GlcNAc modification increases and the phosphorylation 
decreases at pathologically relevant sites on Tau [23]. This increase in O-GlcNAcylation 
blocks hyperphosphorylation and hinders aggregation [24].  
O-GlcNAc also plays a role in diabetes and cancer. Recent research has 
suggested that an increase of the O-GlcNAc modification in prostate cancer cells 
promotes the progression of tumor cells. This elevation of O-GlcNAc is associated with 
an increase in overall patient expiration [25]. Elevated O-GlcNAc levels have also been 
shown to enhance migration/invasion and metastasis in breast cancer cells [26]. Over 
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expression of OGT, the enzyme that adds O-GlcNAc; and GFAT, the rate limiting step 
of the HBP; in various tissues leads to insulin resistance in mice [27]. Insulin is a 
hormone that carries glucose from the bloodstream into cells. Insulin resistance refers 
to the decreased efficiency of insulin for glucose uptake, metabolism and storage. 
Insulin resistance is a major feature and cause of Type 2 diabetes [28].  
1. 8 Inhibitors of hexosaminidase 
O-GlcNAcase is a hexosaminidase that removes the O-GlcNAc modification from 
substrate proteins. Hexosaminidases are enzymes that remove hexosamines. There 
are several different hexosaminidases. When analyzing the O-GlcNAc modification in 
cells that contain a hexosaminidase, it is often necessary to inhibit the hexosaminidase 
in order to increase glycosylation and analyze the effect of hyperglycosylation. 
Streptozotocin (STZ) was one of the first OGA inhibitors used [29]. Recent research 
suggest that STZ acts as a chemical poison rather than an OGA inhibitor [5]. O-(2-
Acetamido-2-deoxy-D-glucopyranosylidenamino) amino-N-phenylcarbamate (PUGNAc) 
is another inhibitor of OGA with a Ki value of 50 nM for OGT purified from rats [5]. 
Although PUGNAc inhibits OGA, it is not specific to OGA and inhibits other 
glycosidases [30]. PUGNAc inhibits lysosomal hexosaminidase with a Ki of 30-40 nM 
[5]. Thiamet-G has a Ki of 21 nM for OGA and is a stable bioactive inhibitor, leading to 
increased tau glycosylation in mice brain [31]. In an effort to create a strong and 
selective inhibitor, Dorfmuller and coworkers developed a class of small molecule OGA 
inhibitors called GlcNAcstatins [32]. This class of inhibitors is more selective towards 
human OGA and increases O-GlcNAcylation by 2 to 3 fold [5].  
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1. 9 Methods for O-GlcNAc detection 
1. 9. 1 Galactosyltransferase-based methods 
Β-1,4-Galactosyltransferase is an enzyme that transfers a single galactose from 
UDP-galactose to a terminal GlcNAc molecule (Figure 1-6b). This enzymatic labeling 
method was used in 1984 by Gerald Hart when he first discovered the O-GlcNAc 
modification [13]. Radioactive 3H-galactose was added to O-GlcNAcylated proteins and 
the radioactivity was detected. This technique can be used to transfer a galactose with a 
chemically reactive group to the O-GlcNAc residue [33]. This allows for biotin labeling, 
which can then be used for chemiluminescent and western blot detection, or enrichment 
for further analysis.  
1. 9. 2 Lectin blot 
A lectin blot is a technique in which a lectin is used to detect a glycoprotein 
(Figure 1-6a). The lectin, which is a protein that recognizes and binds a specific 
carbohydrate and binds carbohydrate based molecules, is conjugated to a fluorescent 
tag for detection. Lectins are found in most animals, plants and microorganisms. Wheat 
germ agglutinin (WGA) is the lectin that recognizes and binds to terminal GlcNAc or N-
acetylneuraminic acid residues [34]. WGA is bound to agarose beads and used as a 
means of affinity purification in order to enrich the glycoprotein for further analysis. 
Although WGA binds O-GlcNAc, it is not always selective. For this reason, other means 
of detection are sometimes necessary.  
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1. 9. 3 Western blot 
Western blots are very similar to lectin blots. Instead of using a lectin to bind and 
detect the protein of interest, primary and secondary antibodies are used (Figure 1-6a). 
Proteins are transferred from a sodium dodecyl sulfate polyacrylamide gel 
electrophoresis (SDS-PAGE) gel onto a nitrocellulose or PVDF membrane. The 
membrane is then blocked. The term blocked refers to the blocking of free space on the 
membrane to insure proper antibody binding. The membrane is probed with the primary 
antibody. This antibody binds to the epitope of interest. CTD 110. 8 and RL-2 are 
common antibodies for the detection of O-GlcNAc. CTD 110. 8 binds specifically to O-
GlcNAc while RL2 less specific. A secondary antibody, which is conjugated to a 
fluorescent tag, binds the primary antibody. Although this method of detection is very 
similar to a lectin blot, it is more selective.  
1. 9. 4 Chemical Derivatization – BEMAD 
Mass spectrometry (MS) techniques that use high energy ionization methods 
tend to fragment the O-GlcNAc modification before it can be analyzed. In 2002 Lance 
Wells applied the beta elimination Michael addition (BEMAD) reaction, a two-step 
organic reaction, to O-GlcNAc-modified proteins [35]. The BEMAD reaction replaces the 
O-GlcNAc modification with another compound that is stable during MS analysis. The 
first step of the reaction is the beta elimination of O-GlcNAc, followed by the addition of 
a new compound via Michael addition of a nucleophile. Dithiothreitol (DTT) or biotin 
pentylamine (BAP) are the nucleophiles of that have been used [36]. At the time, this 
reaction was notable because it allowed detection of O-GlcNAc-modified protein and 
site mapping. Site mapping is a process where the exact amino acid modified is 
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identified. Now, there are lower energy fragmentation techniques that allow the O-
GlcNAc modification to stay intact during site mapping [35].  
 
Figure 1-6 Methods of O-GlcNAc detection. Banerjee, P. S. , G. W. Hart, and J. W. Cho, 
Chemical approaches to study o-glcnacylation. Chemical Society Reviews, 2013. 
42(10): p. 4345-4357 
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1. 10 Methods to study O-GlcNAc-modified proteins  
There have been numerous strategies to study O-GlcNAc-modified proteins. O-
GlcNAc-modified proteins have been extracted from animal tissues. OGT has been 
extracted and used for in vitro glycosylation. OGT has been expressed in E. coli and 
used for in vitro glycosylation. Target proteins have been expressed in human cells that 
have the OGT gene. The aim of methods is to identify O-GlcNAc-modified proteins. 
WGA affinity chromatography is often used to enrich protein samples. The sites of 
glycosylation are then mapped using MS. Mice and fly have been used to study to 
effects of the O-GlcNAc modification on cellular processes related to a specific protein 
[37, 38].  
1. 11 Challenges 
Although there have been major discoveries about the O-GlcNAc modification 
since it was first discovered, there are still many limitations. The greatest of these is the 
sample size. Proteins extracted from animal tissue are low in concentration. The same 
is true for modified proteins expressed in human cells. In vitro reactions are 
normally done on a small scale due to the low concentration of extracted OGT. Human 
OGT expressed in E. coli has also been used for in vitro glycosylation reactions. Limited 
sample concentration has made structural analysis of O-GlcNAc-modified proteins 
impossible. NMR and X-ray crystallography require milligram quantities of protein when 
the methods to date yield only micrograms of O-GlcNAc-modified protein.  
1. 12 In vivo expression of O-GlcNAc-modified protein  
Dysregulation of the O-GlcNAc modification, whether too much or too little, has 
been implicated in disease. Given that the modification is essential for life and has been 
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linked to several diseases, understanding the effect of the modification on protein 
structure is imperative. In this thesis, O-GlcNAc-modified proteins will be expressed in 
vivo. In this particular method, OGT and a target protein are co-expressed in E. coli. 
This method is especially interesting because it enables the expression of large 
amounts of modified target proteins. More importantly, this method allows isotopic 
labeling for NMR structural analysis. E. coli was chosen over mammalian or insect cells 
because it does not carry the OGT gene. E. coli is the most common expression system 
for milligram quantities of protein for NMR and X-ray crystallography structural analysis 
[39]. This method requires molecular cloning of the target proteins and OGT DNA into 
expression vectors, transformation of the vectors into expression cells, protein 
expression and purification. Once the protein has been successfully produced with and 
without the modification, their 3D structures will be determined and compared. E. coli 
requires sources of carbon and nitrogen to synthesize proteins. Growing E. coli with 
15N-ammonium chloride and 13C-glucose produces proteins with isotopically labeled 
backbones and side chains. This method also allows the isotopic labeling of the O-
GlcNAc modification.  
1. 13 Molecular cloning and gene expression 
Molecular cloning is a process where DNA encoding a target protein is inserted 
into a cloning vector. This process is usually achieved through polymerase chain 
reaction (PCR), restriction digestion, and ligation (Figure 1-7). PCR is an experiment 
where a small fragment of DNA is amplified, creating many copies of that fragment. 
PCR consist of 3 steps. First, the DNA is denatured separating it into single strands. 
Primers anneal, or bind, to their consensus sequences at the 3’ end, and elongation 
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occurs. During elongation, RNA polymerase uses DNA base pair components to extend 
the primers, which makes a new double stranded DNA fragment. Every time this 
process occurs, the DNA fragments double. Once the fragment has been amplified, it is 
then digested with restriction enzymes. Restriction enzymes recognize specific DNA 
sequences and cleave them, leaving sticky or overlapping ends. This same digestion is 
done on the cloning vector. In the ligation step, the sticky ends are bound together by a 
ligase. The two pieces of DNA come together to form a plasmid, circular DNA, which is 
then transformed into competent E. coli cells. These cells make several copies of the 
plasmid that is used for protein expression.  
1. 14 Recombinant protein expression and purification 
Recombinant protein expression is a process in which DNA corresponding to a 
target protein is expressed from a vector. The expression vector is made of DNA that 
has all the necessary promoters and operators for protein expression in a bacterial host. 
The cloned and recombined DNA is transformed into E. coli and isopropyl β-D-1-
thiogalactopyranoside (IPTG) is used to induce expression of the protein. The cells are 
harvested and lysed through mechanical or chemical force. Soluble proteins are 
separated from the cell debris by centrifugation. The protein of interest is isolated 
through a purification process such as affinity chromatography. Affinity chromatography 
is a process were a protein is tagged with the addition of some sequence of amino acids 
that has a moderate binding affinity for a compound immobilized on some type of resin. 
For example, nickel affinity chromatography uses the affinity between 6 histidine 




Figure 1-7 Steps involved in molecular cloning. http://cnx. org/contents/185cbf87-c72e-
48f5-b51e-f14f21b5eabd@9. 45:88/Biology 
1. 15 Co-expression of target proteins with OGT 
O-GlcNAc transferase (OGT) is the enzyme that adds O-GlcNAc to a target 
protein. Scientists began to question if a co-expression of OGT and a target protein 
would produce O-GlcNAc-modified protein. Although the mechanism of OGT is not fully 
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understood, we know that UDP-GlcNAc is the substrate for the addition of the O-
GlcNAc modification. E. coli produces UDP-GlcNAc within the cells, making the 
expression of O-GlcNAc-modified proteins possible in a co-expression system. David 
Vocadlo has expressed a few O-GlcNAc-modified proteins using this method [24]. 
Expressing the modified protein in E. coli permits 15N and 13C isotopic labeling of the 
protein, as well as the modification, for NMR structural analysis.  
1. 16 NMR 
NMR is an analytical technique where the nuclear spins of a molecule are 
aligned by a constant magnetic field. An external oscillating magnetic field generated by 
a radiofrequency pulse is used to transfer a population of nuclei into a higher energy 
state with phase coherence. As the nuclei relax back to their lower energy state, the 
oscillating magnetic field generated by the coherent spins is detected. To date, there is 
no protein structure with the O-GlcNAc modification available by NMR or X-ray 
crystallography. One of the major setbacks of X-ray crystallography is that the technique 
depends on the protein’s ability to be crystallized. It also only gives a static view of a 
protein’s structure. NMR allows for the detection of conformational changes under 
physiological conditions. Although NMR is limited by the size of proteins that can be 
analyzed (about 30 kDa), it is not a problem for this research because all target proteins 
are within the applicable size range.  
Methods for determination of protein structure by NMR have become standard, 
starting with backbone and side chain peak assignment, followed by distance and 
restraint measurements, and concluding with the final calculation of the structure. 1H-
15N heteronuclear single quantum coherence spectroscopy (HSQC) is the first NMR 
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experiment performed on the purified isotopically labeled protein. This experiment gives 
one peak for each amide group from each amino acid in the protein. 2D experiments 
show the correlation between two nuclei, in this case the 1H attached to the 15N of the 
amide group. Side chains containing amines also appear in 1H-15N HSQC experiments 
as well. The dispersion, intensity and number of peaks gives valuable information about 
the protein sample. Spectra with narrow dispersion between 7-8 ppm indicate that the 
protein is unfolded or aggregated. Peak intensity is related to the concentration of the 
sample and the oligomerization state. Optimal sample conditions yield greater than 95% 
of expected backbone peaks. Once the conditions are optimized, additional experiments 
are done for further assignments. The next experiment collected is CBCANH. This 3D 
experiment shows which Cα’s and Cβ’s are connected to each amide group previously 
identified from the 1H -15N HSQC experiment (Figure 1-8). In most cases, there are two 
Cα’s and two Cβ’s peaks for each amide, the Cα/Cβ pair on the previous residue and 
the Cα/Cβ pair directly connected to the amide. These Cα/Cβ pairs are indicated by the 
residue number i and i -1. Because the i-1 Cα/Cβ pair is not always visible, an additional 
experiment is done. CBCA(CO)NH only shows peaks corresponding to Cα/Cβ i-1. 
These experiments allow scientists to identify the amino acid backbone peaks of the 
protein. Chemical shifts give information about the identity of the side chains and further 
experiments can be done if required.  
The next set of experiments performed gives information about the secondary 
structure by measuring scalar coupling (J-coupling). J-coupling is a through bond 
measurement that gives information about bond angles. Nuclear overhauser effects 
(NOEs) are through space measurements and give information about protein 
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conformation. NOEs between neighboring residues also give secondary structural 
information. 2D Nuclear overhauser spectroscopy (NOESY) is used to measure 
distances between protons in close proximity. 15N-NOESY experiments give NOE 
measurements for all hydrogens within 5 Å of an NH group. 13C-NOESY measures all 
the hydrogens within 5 Å of a CH group. Once the NOESY experiments are completed, 
there are automated programs that assign the peaks. These assignments, along with 
the previous assignments and distance restraints, are used to calculate a protein 
structure [40].  
 
Figure 1-8 CBCANH experiment. http://www. protein-nmr. org. 
uk/pictures/experiment_types/cbcanh. pngc  
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Chapter 2: E. coli sabotages the in vivo production of O-linked-N-
acetylglucosamine (O-GlcNAc) modified proteins 
2. 1 Introduction 
cAMP response element binding protein (CREB1) is a transpiration factor, that 
plays a major role in the nervous system and brain. CREB1 is present in both neurons 
and glial cells, which are the major components of the nervous system. CREB1 is well 
known for its essential role in long-term memory and learning [41]. CREB1 is a human 
protein that contains 341 amino acids divided into 4 domains. It includes 2 hydrophobic 
and glutamine rich domains:  Q1 at the N-terminus and Q2 in the middle of the 
sequence. A kinase-inducible domain, KID, separates the Q1 and Q2 domains. The 
bZip, basic leucine zipper, domain is at the C-terminus. CREB1 binds to DNA and 
activates expression of proteins that contribute to synaptic plasticity [42]. Synaptic 
plasticity refers to the process by which synapses are modified in structure and function 
in response to different stimuli or environmental cues. Activity-dependent synaptic 
plasticity is thought to be the underlying process of learning and memory [43]. Josselyn 
et al. showed the first direct evidence that increasing CREB1 levels in a defined 
mammalian brain region enhances long-term memory formation [44].  
CREB1 is O-GlcNAcylated in vivo. The modification occurs at two residues 
between amino acids 256-261 in the Q2 domain at S1er-260, Thr-256, Thr-259, or Thr-
261 [41]. Transcriptional activity is repressed when CREB1 is modified with O-GlcNAc 
because O-GlcNAc it inhibits CREB1’s association with the coactivator, TATA-
1 This chapter previously appeared as: Octavia Y. Goodwin, Maggie S. Thomasson, Aaron J. Lin, Michelle 
M. Sweeney, Megan A. Macnaughtan. E. coli sabotage the in vivo production of O-linked-β-N-
acetylglucosamine-modified proteins. Journal of Biotechnology 168 (2013) 315-323. 
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associated factor (TAFII130) [41]. 
 
Figure 2-1The O-GlcNAc modification of CREB1 disrupts binding with TAFII130.  
Recent studies have shown that inhibition of O-GlcNAcylation leads to enhanced axonal 
and dendritic growth and long-term memory [18]. A study done in mice showed that 
mice expressing O-GlcNAcylated CREB1 had a decrease in long-term memory 
compared to mice that expressed non-glycosylated CREB1 . In this chapter I describe 
how CREB1 was cloned, expressed, and glycosylated in vivo for structural analysis.  
2. 2 Materials and methods 
2. 2. 1 Materials 
 Ovalbumin, hen egg white lysozyme, N-acetylglucosaminidase from Canavalia 
ensiformis (Jackbean), fluorescein-conjugated wheat-germ agglutinin (FITC-WGA), 
glycerol, maleic acid, O-(2-acetamido-2-dexoyd-glucopyranosylidene)amino-N-
phenylcarbamate (PUGNAc), 4,4-dimethyl-4-silapentane-1-sulfonic acid (DSS), sodium 
chloride (NaCl), sodium phosphate dibasic, sodium phosphate monobasic, 
bromophenol blue, dimethylformamide, 4-methylumbelliferyl-N-acetylglucosaminide 
(MU-GlcNAc), sodium carbonate, p-nitrophenyl-β-N-acetylglucosamine (pNP-GlcNAc), 
Coomassie brilliant blue R250, sodium dodecyl sulfate (SDS), glycine, 
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tris(hydroxymethyl)aminomethane (tris), 2-mercaptoethanol, His-Select Ni-affinity gel, 
imidazole, urea, acetic acid, methanol, and kanamycin were purchased from Sigma-
Aldrich. pET-28b vector, Rosetta(DE3) cells, Tuner(DE3) cells, BugBuster protein 
extraction reagent, and ampicillin were purchased from EMD Millipore/Novagen. A UNO 
S1 cation exchange column, Precision Plus Protein Unstained Standards, 4–20% mini-
PROTEAN TGX precast gels, immun-blot low fluorescence PVDF membrane, and 
Laemmli buffer were purchased from Bio-Rad. 2-log DNA ladder, 10-beta cells, Taq 5X 
master mix, T4 DNA ligase, NdeI restriction enzyme, and XhoI restriction enzyme were 
purchased from New England Biolabs. BioReagents EZ-Run Rec Protein Ladder, anti-
O-GlcNAc MAb CTD 110. 6, and DyLight 550-conjugate Goat anti-Mouse IgG 
secondary antibody were purchased from Thermo Scientific/Pierce Antibodies. Luria 
broth (LB) and agar were purchased from BD Biosciences. Artic Express(DE3) cells and 
BL21-Gold(DE3) cells were purchased from Agilent Technologies, Strategene Products 
Division. OverExpress C41(DE3) cells and OverExpress C43(DE3) cells were 
purchased from Lucigen. Other chemicals and materials used include a glycopeptide 
(SVES(β-O-GlcNAc)GSADAK-NH2, Sussex Research), deuterated water (D2O, 
Cambridge Isotope Laboratories), isopropyl-D-1-thiogalactopyranoside (IPTG, 
Affymetrix Anatrace), primers (Integrated DNA Technologies), a TSKgel G3000 SWxl 
gel filtration column (Tosoh Bioscience LLC), full-length cDNA sequence of human 
cAMP responsive element-binding protein in pCMV-Sport 6 vector (CREB1, Invitrogen), 
QIAprep spin miniprep kit (Qiagen), Costar 96 well UV transparent flat bottom plates, 4 
mm susceptibility matched NMR tube (D2O-matched, Shigemi Inc. ), K-12 nagZ 
knockout strain (JW1093-1) and K-12 parent strain (BW25113) (Keio Collection, E. coli 
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Genetic Resources at Yale, CGSC, The Coli Genetic Stock Center) [45], and clone 
HsCD00331895 of the F-actin binding domain of Abelson tyrosine-kinase 2 (ABL2-
FABD) in pET15 vector (DNASU Plasmid Repository, PSI:Biology-Materials Repository) 
[46]. All water used was supplied from a Millipore Direct-Q 3 ultrapure water system.  
2. 2. 2 Cloning and expression vectors 
The human O-GlcNAc transferase (OGT) was expressed using the pET-43. 1 
Ek/LIC vector with the full-length sequence provided by Dr. John Hanover [47]. The 
pET-43. 1 Ek/LIC-OGT includes an N-terminal NusA-, 6XHis-, and S-tags. The 
sequence of three substrate protein domains were cloned into the expression vector, 
pET-28b, with an N-terminal 6XHis tag: the second glutamine-rich domain, Q2, of 
human cAMP responsive element-binding protein (CREB1-Q2, amino acids 160–283), 
the Q2 and bZIP domains of CREB1 (CREB1-Q2-bZIP, amino acids 160–341), and the 
F-actin binding domain of Abelson tyrosine-kinase 2 (ABL2-FABD). CREB1-Q2 and 
CREB1-Q2-bZIP were cloned from cDNA of the full-length sequence using PCR primers 
and the restriction enzymes NdeI and XhoI. The forward primer used was 5’-
TACGTCCATATGACTTCAGCACCTGCCATC-3’, and the reverse primer for CREB1-
Q2 was 5’-TAGCTGCTCGAGTCATGCTGCTTCTTCAGCAGG-3’ and for CREB1-Q2-
bZIP was 5’-TAGCTGGCGGCCGCTCAATCTGATTTGTGGCAGTA-3’. ABL2-FABD 
was cloned from a pET-15 vector (clone HsCD00331895, PSI:Biology-Materials 
Repository) using restriction enzymes, NdeI and XhoI. The pET-43. 1 Ek/LIC-OGT, 
pET-28b-CREB1-Q2, pET-28b-CREB1-Q2-bZIP, and pET-28b-ABL2FABD were each 
transformed into 10-beta E. coli cloning cells. Each plasmid was purified from a 5 mL 
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culture and sequenced (GeneLab DNA sequencing service at Louisiana State 
University).  
2. 2. 3 E. coli cultures and protein co-expression 
BL21-Gold(DE3) E. coli competent cells were transformed with pET-43. 1-OGT 
and a substrate vector (either pET-28b-CREB1-Q2, pET-28b-CREB1-Q2-bZIP, or pET-
28b-ABL2-FABD), and selected on agar plates supplemented with ampicillin and 
kanamycin. The expression strains were each grown in LB media at 37 °C. At an optical 
density at 600 nm of 0. 6–0. 8, the culture was induced with 0. 5 mM IPTG and grown at 
37 °C for 3 h, unless otherwise stated. The cells were harvested using BugBuster 
protein extraction reagent and French press and/or ultrasonication followed by 
centrifugation at 30,000 g for 30 min at 4 °C. For some experiments, OGT and the 
substrate proteins were purified using His-Select Ni-affinity gel media using gravity flow. 
Cleared lysate was loaded onto 1 mL of Ni-affinity media equilibrated with 50 mM 
sodium phosphate, 300 mM NaCl, pH 8. 0 buffer. The media was washed with 20 mL of 
buffer with 10 mM imidazole, and the protein was eluted with 10 mL of buffer with 300 
mM imidazole. Having 6XHis-tags on both OGT and the substrate proteins allows for 
simultaneous purification and evaluation of protein expression levels using SDS-PAGE. 
OGT (∼170 kDa) and the substrate proteins (<25 kDa) can be separated using gel 
filtration chromatography if needed, or alternatively, OGT can be cloned without the 
6XHis tag. Separation of OGT and the substrate proteins was not necessary for the 
experiments presented in this chapter.  
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BL21-Gold(DE3) E. coli with empty pET28b vector, K-12 parent E. coli, and K-12 
∆nagZ E. coli were each grown in 250 mL of LB media at 37 °C. At an optical density at 
600 nm of 0. 6, 1. 0 mM IPTG was added to the BL21-Gold(DE3) culture only and all 
cultures were incubated for 3 h at 37 °C. The cells from each culture were harvested at 
3000 g for 10 min, suspended in 12 mL of Bugbuster protein extraction reagent, and 
lysed using French press. Cleared lysate was prepared by centrifugation at 30,000 g for 
30 min.  
2. 2. 4 O-GlcNAc detection and quantification 
SDS-PAGE gels and blots were used to determine the relative amount of O-
GlcNAc-modified protein compared to total protein. Samples of cleared lysate and 
insoluble pellet were prepared for SDS-PAGE in Laemmli buffer with 5% v/v 2-
mercaptoethanol and incubated at 95 °C for 15 min. The samples were loaded into a 4–
20% gel and run at 125 V for 60 min in 25 mM tris, 192 mM glycine, 0. 1% SDS, pH 8. 3 
buffer. Protein ladder was run on each gel, and duplicate gels were run when blot 
analysis was needed. The gel was stained with Coomassie Brilliant Blue R250 solution 
(0. 1% R250, 50% methanol, 40% water, 10% acetic acid), de-stained (50% water, 40% 
methanol, 10% acetic acid), and imaged using a GE Typhoon 9410 imager or Fotodyne 
Apprentice system. The contrast and brightness of the images were adjusted using 
Microsoft Powerpoint software or ImageJ software to improve the quality of the images 
for publication [48].  
Blotting methods included both lectin and western blots. Fluorescein-conjugated 
wheat-germ agglutinin was used for the lectin blots. Anti-O-GlcNAc MAb CTD 110. 6 
and DyLight 550 conjugate Goat anti-Mouse IgG secondary antibody were used for the 
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western blots. Hen egg white lysozyme and ovalbumin were used as positive controls 
for the western blots and lectin blots, respectively. All blots were imaged using the GE 
Typhoon 9410 imager in the Louisiana State University AgCenter Biotechnology 
Laboratory, Protein Facility. ImageJ software was used to measure the band densities 
from the Coomassie-stained SDS-PAGE gels (relative total protein concentration) and 
from the blots (relative O-GlcNAc-modified protein concentration) [48]. The background 
signal was subtracted and the ratios of the blot to gel densities were calculated. The 
error calculated from multiple background measurements was propagated and is 
represented as error bars.  
2. 2. 5 Partial purification of E. coli β-N-acetylglucosaminidase 
E. coli β-N-acetylglucosaminidase was partially purified from the cleared lysate of 
BL21-Gold(DE3) expressing empty pET-28b, K-12 parent, and K-12 ∆nagZ cultures 
using cation exchange chromatography (CXC). A BioLogic DuoFlow 10 system with UV 
detection and a fraction collector was used for all chromatography experiments. Cleared 
lysate (12 mL) was separated using a UNO S1 cation exchange column into 1 mL 
fractions using a buffer gradient of 20 mM sodium phosphate pH 7. 0, from 0 to 0. 5 M 
NaCl. The fractions were analyzed for β-N-acetylglucosaminidase activity using the MU-
GlcNAc fluorescent well-plate assay described in Section 2. 6. The active fractions from 
the cleared lysate of BL21-Gold(DE3) expressing empty pET-28b were combined and 
used to determine enzyme kinetics and activity toward a glycopeptide. The K-12 parent 
and K-12 ∆nagZ fractions were used to test for other β-N-acetylglucosaminidase activity 
toward MU-GlcNAc. The cleared lysate from the K-12 ∆nagZ culture was used to test 
for other β-N-acetylglucosaminidase activity toward a glycopeptide.  
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2. 2. 6 E. coli β-N-acetylglucosaminidase detection assays 
Spectrophotometric and fluorescence well-plate methods were used to measure 
β-N-acetylglucosaminidase activity. A solution of a chromophoric, β-N-
acetylglucosaminidase substrate, pNP-GlcNAc, was prepared in 50 mM tris-maleate, 
20% glycerol, pH 7. 7 at 1. 0 mg/mL (2. 9 mM) and preheated to 37 °C. In a 96 
wellplate, 20 µL of sample (cleared lysate or chromatography fraction) was added to 90 
µL of the pNP-GlcNAc solution (final concentration was 2. 4 mM) and incubated at 37 
°C for 30 min. The reaction was quenched with 200 µL of 42 mg/mL (396 mM) sodium 
carbonate, which stopped the reaction and converted any cleaved p-nitrophenol to 
yellow nitrophenolate. The absorbance at 405 nm was measured with a Biotek 
PowerWave XS microplate spectrophotometer and converted to nmoles of 
nitrophenolate formed per mL of fraction/min using an extinction coefficient of 18,100 M-
1cm-1 for nitrophenolate [49]. An assay blank was run with 20 µL of buffer (lysis buffer or 
chromatography buffer) in place of the sample; and, a sample blank was run with 90 µL 
of tris-maleate buffer in place of substrate. Each sample and blank were run in triplicate 
where indicated. For triplicate measurements, the average absorbance and standard 
deviation for each sample and blank were calculated. Detection of β-N-
acetylglucosaminidase activity in the chromatography fractions were done by Maggie 
Thomasson.  
For the fluorescent β-N-acetylglucosaminidase activity assay, a stock solution of 
4-methylumbelliferyl-β-N-acetylglucosaminide, MU-GlcNAc, was prepared at 25 mM in 
dimethylformamide. A working solution of 1. 5 mM MU-GlcNAc for well plate assays 
was made by diluting the stock solution in 100 mM sodium phosphate buffer, pH 7. 4. 
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The working solution was preheated to 37 °C. For the 96 well-plate assay, 20 µL of 
sample (cleared lysate or chromatography fraction) was added to 90 µL of the MU-
GlcNAc working solution (final MU-GlcNAc concentration was 1. 2 mM) and incubated 
at 37 °C for 30 min. The fluorescence intensity was measured with an excitation 
wavelength of 372 nm and emission wavelength of 445nm using a Perkin Elmer Wallac 
Victor2 V fluorescence plate reader, housed in the Louisiana State University AgCenter 
Biotechnology Laboratory, Protein Facility. A positive control was run using 1 µL of β-N-
acetylglucosaminidase from C. ensiformis (Jack bean) in 19 µL of buffer (lysis buffer or 
chromatography buffer) with 90 µL of the working MU-GlcNAc solution. A negative 
control was run using 20 µL of buffer (lysis buffer or chromatography buffer) with 90 µL 
of the working MU-GlcNAc solution. Each sample and blank were run in triplicate where 
indicated. For triplicate measurements, the average fluorescence intensity and standard 
deviation for each sample and blank were calculated. This fluorescent assay was done 
by Maggie Thomasson.  
2. 2. 7 Kinetic assays 
The Michaelis–Menten constants (Km) for MU-GlcNAc and pNP-GlcNAc and the 
inhibition constant (Ki) for PUGNAc were determined for the E. coli β-N-
acetylglucosaminidase using the pooled β-N-acetylglucosaminidase-active CXC 
fractions (see Section 2. 5). For the pNP-GlcNAc reactions, three replicate samples of 
0, 0. 05, 0. 5, 5 mM pNP-GlcNAc and 80 µL of active CXC fraction were mixed in 50 
mM sodium phosphate, 500 mM sodium chloride, pH 7. 1 to a final volume of 100 µL. In 
addition to the sample blank (0 mM pNP-GlcNAc), an assay blank was made in triplicate 
with 5 mM pNP-GlcNAc in buffer. The samples were incubated at 37 °C. One set of the 
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triplicate samples was quenched with 200 µL of 396 mM sodium carbonate at 10, 15, 
and 20 min. The formation of product was measured as described in Section 2. 6.  
The Km for MU-GlcNAc and the Ki for PUGNAc were determined using sets of 
three replicate samples at 0, 13. 6, 16. 4, 20. 4, 27. 3, 40. 9, and 81. 8 µM MU-GlcNAc 
with 0, 200, and 500 nM PUGNAc. Each sample volume was 110 µL with 20 µL of 
active CXC fraction and 100 mM sodium phosphate, pH 7. 4 buffer. The fluorescence 
intensities of the samples were measured at room temperature after 4, 9, and 14 min 
using a fluorescence plate reader as described in Section 2. 6. The kinetics assay was 
done by Maggie Thomasson.  
2. 2. 8 Kinetic analysis 
Initial velocities (V) at each substrate (S) concentration were determined using 
least squares fitting to a linear function, and the average values were calculated for 
triplicate measurements. The data were then analyzed by nonlinear regression analysis 
using the computer programs of Cleland (1979). Initial velocities were fit to Eq. (1) to 
determine the maximal velocity (Vmax) and the Michaelis–Menten constant (Km).  
Eq. (1)  
Data for competitive inhibition were fit to Eq. (2), where I is the concentration of 
PUGNAc and Ki is the inhibition constant. The kinetics analysis was done by Maggie 
Thomasson.  
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Eq. (2)  
2. 2. 9 Inhibition of E. coli β-N-acetylglucosaminidase activity 
Cleared lysate from a BL21-Gold(DE3) culture was tested for β-N-
acetylglucosaminidase activity using the pNP-GlcNAc spectrophotometric assay 
described in Section 2. 6. PUGNAc was added to 20 µL of lysate at varying 
concentrations (0, 1, and 2 µM PUGNAc) and mixed with 90 µL of 1. 0 mg/mL pNP-
GlcNAc. Conditions, blanks, and measurements are the same as described in Section 
2. 6.  
Changes in the relative amount of O-GlcNAc-ABL2-FABD were measured for co-
expression cultures grown with 0, 1, 2, and 10 µM PUGNAc. PUGNAc was added to the 
growth media of BL21-Gold(DE3) cells co-expressing pET43. 1 Ek/LIC-OGT and 
pET28b-ABL2-FABD. The cultures were grown, harvested, and lysed as described in 
Section 2. 3. The soluble and insoluble proteins from each culture were analyzed with 
SDS-PAGE and western blot as described in Section 2. 4. The relative amount of O-
GlcNAc was measured as described in Section 2. 4.  
2. 2. 10 NMR experiments to detect E. coli β-N-acetylglucosaminidase hydrolysis 
of an O-GlcNAc-modified peptide 
To evaluate the activity of the E. coli β-N-acetylglucosaminidase toward protein 
O-GlcNAc, a synthetic O-GlcNAc-modified peptide (SVES(β-O-GlcNAc)GSADAK-NH2) 
was incubated with partially purified, E. coli β-N-acetylglucosaminidase and K-12 ∆nagZ 
lysate. Each reaction mixture was analyzed with 1H NMR to observe the 1H anomeric 
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signal of any released α-GlcNAc (5. 2 ppm). This signal was chosen because it has 
relatively little background interference. The reaction mixtures contained 200 µM 
glycopeptide, 100 µL of β-N-acetylglucosaminidase-active CXC fraction or K-12 ∆nagZ 
lysate, 50 mM sodium phosphate, 500 mM NaCl, pH 7. 1 buffer, 10% D2O, and trace 
DSS (to lock and reference the NMR signal, respectively).  
A glycopeptide control, sample control, and sample control with 200 µM N-
acetylglucosamine (GlcNAc) were prepared with 100 µL of CXC buffer instead of active 
fraction or lysate, 3. 0 µL of water instead of glycopeptide stock solution, and 1. 3 µL of 
20 mM GlcNAc plus 2. 7 µL of water instead of glycopeptide stock solution, respectively. 
The samples were either incubated at 37 °C for 5 h (CXC β-N-acetylglucosaminidase-
active fraction) or 22. 5 h (K-12 ∆nagZ lysate). The glycopeptide control and sample 
controls were treated with the same conditions. The reactions were performed one time. 
The reaction mixtures and controls were analyzed in 4 mm D2O-susceptibility matched 
tubes. 1H NMR spectra of the samples were collected on a 700 MHz Varian NMR 
equipped with a 5 mm HCN probe. The spectra were collected at 20 °C with 
presaturation of water (1 s saturation time, 12 dB saturation power), 1 s acquisition time, 
1 s recycle delay, 7000 Hz spectral width, 30 dB gain, and 2048 scans. Data 
processing, line broadening (1 Hz exponential), chemical shift referencing, baseline 
correction, peak height measurements, and signal-to-noise calculations were performed 
with VnmrJ 3. 2 software (Agilent). The amount of released GlcNAc was estimated by 
comparing the peak intensities at 5. 198 ppm (left peak of the anomeric 1H α-GlcNAc 
doublet) of the reaction mixture to the control sample with 200 µM GlcNAc. For the 
glycopeptide reaction with K-12 ∆nagZ lysate, the limit of quantitation (S/N = 10) was 
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calculated using the S/N of the 1H anomeric α-GlcNAc peak in the control sample with 
200 µM GlcNAc.  
2. 3 Results and discussion 
2. 3. 1 Co-expression of OGT with substrate proteins using E. coli 
The second glutamine-rich domain of human CREB1 (CREB1-Q2) and the Q2 
and bZIP domains of CREB1 (CREB1-Q2-bZIP) were co-expressed with full-length 
human OGT in BL21-Gold(DE3) E. coli. Even though these vectors have the same 
origin of replication, the different antibiotic resistance prevents incompatibility [50]. The 
CREB1-Q2 and CREB1-Q2-bZIP domains were chosen as substrate proteins because 
the Q2 domain is natively modified with at least two O-GlcNAc molecules that suppress 
CREB1-activated transcription [17]. The co-expression cultures were lysed and 
separated into soluble lysate and insoluble pellet fractions. The soluble lysate and pellet 
were analyzed with Coomassie SDS-PAGE and lectin blot. The results for the co-
expression of OGT with CREB1-Q2 and CREB1-Q2-bZIP are shown in Figures 2-2 and 
2-3, respectively. Figures 2-2a and 2-3a show the SDS-PAGE gel images for Ni-affinity 
purified CREB1-Q2 and CREB1-Q2-bZIP soluble lysate. CREB1-Q2 is highly expressed 
and soluble, while CREB1-Q2-bZIP is mainly found in the pellet. The additional bands in 
the Ni-affinity purified lysate in Figure 2-2a are E. coli background proteins and 6XHis-
tagged OGT (with multiple translational truncations due to rare codons). Figures 2-2b 
and 2-3b show the lectin blots corresponding to the SDS-PAGE gels. The dark bands 
indicate where FITC-WGA bound O-GlcNAc-modified proteins. The presence of O-
GlcNAc was also confirmed with an anti-O-GlcNAc MAb CTD 110. 6 western blot of Ni-
affinity purified protein from the expression of CREB1-Q2-bZIP (pET-28b-CREB1-Q2-
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bZIP) without and with co-expression of OGT (pET-43. 1-OGT) in E. coli BL21-
Gold(DE3) (see Supplementary Figure 1). In both lectin blots (Figures 2-2 and 2-3), only 
insoluble CREB1-Q2 and CREB1-Q2-bZIP were modified with O-GlcNAc.  
The absence of soluble, O-GlcNAc-modified protein from the co-expression 
system was unexpected. Others have shown that E. coli co-expression of OGT with 
substrate protein produce O-GlcNAc-modified proteins in vivo, but the solubility of the 
modified proteins was not specifically addressed in these studies [51-53].  
 
Figure 2-2 The Ni-affinity purified soluble lysate and pellet from co-expression of 
CREB1-Q2 (pET-28b-CREB1-Q2) and OGT (pET-43. 1-OGT) in E. coli BL21-
Gold(DE3) analyzed with (a) Coomassie-stained SDS-PAGE and (b) FITC-WGA lectin 




Figure 2-3  The soluble lysate and pellet from co-expression of CREB1-Q2-bZIP 
(pET28b-CREB1-Q2-bZIP) and OGT (pET-43. 1-OGT) in E. coli BL21-Gold(DE3) 
analyzed with (a) Coomassie-stained SDS-PAGE and (b) FITC-WGA lectin blot 
detecting O-GlcNAc. The bands corresponding to CREB1-Q2-bZIP are indicated with 
asterisks.  
From Figure 2-3a, CREB1-Q2-bZIP shows little soluble protein in the SDS-PAGE 
image, so observing only O-GlcNAc-modified CREB1-Q2-bZIP in the pellet is not 
informative. However, the solubility of the CREB1-Q2 domain is good, but the O-
GlcNAc-modified protein only occurs in the pellet. To improve the solubility of the O-
GlcNAc-modified proteins, the co-expression of OGT with CREB1-Q2 and CREB1-Q2-
bZIP was tested using additional E. coli expression strains at various conditions. 
Rosetta, C41, and C43 E. coli strains were induced with 0. 5 mM IPTG and grown at 37 
°C for 3 h and 18 °C for 16 h. The Tuner E. coli strain was grown at the same 
temperatures but with 0. 25 mM–1 mM IPTG. Arctic express E. coli cells were induced 
with 0. 5 mM IPTG and grown at 4 °C and 12 °C for 24 h. Regardless of the type of E. 
coli expression strain or conditions used, the O-GlcNAc-modified CREB1-Q2-bZIP and 
CREB1-Q2 proteins were only found in the pellet (data not shown).  
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To circumvent the possibility that O-GlcNAc-modified CREB1-Q2 and CREB1-
Q2-bZIP are inherently insoluble, the F-actin binding domain of Abelson tyrosine-kinase 
2 (ABL2-FABD, also known as ARG, Abelson-related gene protein) was selected as a 
third test protein. ABL2-FABD was selected because it expresses in high yield with high 
solubility in E. coli, actin-binding proteins have been shown to be regulated by O-
GlcNAc, and ABL2-FABD is predicted to have two sites of O-GlcNAc modification [54-
57].  
 
Figure 2-4  ABL2-FABD (pET-28b-ABL2-FABD) and OGT (pET-43. 1-OGT) were co-
expressed in E. coli BL21-Gold(DE3) with increasing concentrations of PUGNAc in the 
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growth media (0, 1, 2, and 10 µM PUGNAc). The soluble lysate (S) and pellet (P) from 
each culture was analyzed with (a) Coomassie-stained SDS-PAGE and (b) anti-O-
GlcNAc MAb CTD 110. 6 western blot. HEWL was used as a positive control in the last 
lane. (c) A plot of the relative band density of the western blot band to the Coomassie-
stained SDS-PAGE gel band (indicated with an asterisk). For each band in (a) and (b), 
the background density was measured thrice, subtracted from each band, and used to 
estimate the propagated measurement error (represented as error bars in (c)).  
Figure 2-4a (Lanes 2 and 3) shows an SDS-PAGE image of the soluble lysate 
and pellet from ABL2-FABD co-expressed with OGT. The ABL2-FABD protein is 
abundant in both the lysate and pellet, but the western blot image in Figure 2-4b (Lanes 
2 and 3) shows small amounts of O-GlcNAc-modified ABL2-FABD only in the pellet. 
The absence of soluble O-GlcNAc-modified protein from the co-expression system 
suggests two possibilities: (1) the modification causes the proteins to precipitate and/or 
(2) the O-GlcNAc modification is being cleaved by an endogenous E. coli enzyme in the 
cytoplasm. The second possibility assumes that the insoluble, O-GlcNAc-modified 
proteins are protected from the suspected E. coli β-N-acetylglucosaminidase activity.  
2. 3. 2 Inhibiting NagZ activity in E. coli increases in vivo O-GlcNAc modification 
NagZ, the only E. coli β-N-acetylglucosaminidase identified, is suspected to be 
the enzyme that deglycosylates soluble O-GlcNAc-modified protein from the co-
expression system. The existence of an O-GlcNAc transferase in E. coli has been ruled 
out but the E. coli β-N-acetylglucosaminidase, NagZ, has not been tested for activity 
toward O-GlcNAc-modified peptides or proteins [58]. NagZ was first purified from K-12 
E. coli and characterized using pNP-GlcNAc in a spectrophotometric assay [59]. The 
soluble, cytoplasmic enzyme was found to specifically cleave O-β-linked GlcNAc. Later 
characterization of K-12 NagZ demonstrated its role in peptidoglycan recycling by 
cleaving the GlcNAc-(1,4)-MurNAc bond (MurNAc, N-acetylmuramic acid) with a Km of 
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35 µM for the anhydro-disaccharide [60, 61]. A null mutant showed that NagZ was not 
essential to E. coli growth and morphology and was the only E. coli β-N-
acetylglucosaminidase [59, 60]. It is possible that NagZ has activity toward O-GlcNAc-
modified proteins because it is similar to human O-GlcNAcase (OGA) in substrate (pNP-
GlcNAc) and inhibitor (PUGNAc). Human OGA cleaves pNP-GlcNAc and is inhibited by 
PUGNAc [62, 63]. K-12 NagZ, which has 99% amino acid identity to BL21-Gold(DE3) 
NagZ, has a pNP-GlcNAc Km of 0. 31–0. 43 mM [59, 61]. PUGNAc is a potent inhibitor 
of Vibrio cholerae NagZ (Ki = 48 nM), a homolog of E. coli NagZ with 56% amino acid 
sequence identity [64]. Following the hypothesis that NagZ cleaves O-GlcNAc from 
modified proteins in the co-expression system, PUGNAc was tested as an inhibitor of 
the enzyme in vitro and in vivo.  
The MU-GlcNAc Km and the PUGNAc Ki of BL21-Gold(DE3) E. coli β-N-
acetylglucosaminidase were determined using partially purified β-N-
acetylglucosaminidase from BL21-Gold(DE3) lysate. β-N-Acetylglucosaminidase-active 
CXC fractions were identified with the MU-GlcNAc well-plate assay and pooled together 
(Supplementary Figure 2). The MU-GlcNAc Km and the PUGNAc Ki were determined by 
measuring the formation rate of 4-methylumbelliferone with a fluorescence plate reader 
at varying MU-GlcNAc and PUGNAc concentrations. The data shown in Figure 2-5 were 
globally fit to competitive, noncompetitive, and uncompetitive inhibition models using 
nonlinear regression analysis, and the competitive model gave the best fit. This result is 
expected since PUGNAc is a competitive inhibitor of other β-N-acetylglucosaminidases 
and has been shown to bind at V. cholerae NagZ’s active site [62, 64, 65]. The best fit 
to Eqs. (1) and (2) give a Km of 5. 6 ± 1. 2 µM MU-GlcNAc and a Ki of 25. 5 ± 4. 6 nM 
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PUGNAc. These results are similar to the Km of K-12 NagZ (35 µM anhydro-
disaccharide) and the Ki of V. cholerae NagZ (Ki = 48 nM PUGNAc), respectively [61, 
64].  
Even though PUGNAc is a strong inhibitor of partially purified E. coli β-N-
acetylglucosaminidase, the effectiveness of the inhibitor is reduced in cleared lysate. 
The E. coli β-N-acetylglucosaminidase activity in cleared lysate was tested with the 
addition of 0, 1, and 2 µM PUGNAc.  
 
Figure 2-5  The initial velocities of E. coli β-N-acetylglucosaminidase, partially purified 
with CXC from BL21-Gold(DE3) cleared lysate, at varying MU-GlcNAc concentrations 
and with different concentrations of PUGNAc. The points represent the observed 
velocities, and the lines represent the best fits of the data to Eqs. (1) and (2).  
The results of this assay (Figure 2-6) show that PUGNAc inhibits the β-N-
acetylglucosaminidase activity, but not as well as expected for a Ki of 25. 5 nM. To rule 
out the possibility that E. coli β-N-acetylglucosaminidase has a low pNP-GlcNAc Km, the 
Km was measured using partially purified β-N-acetylglucosaminidase from BL21-
Gold(DE3) lysate. The best fit of the data (Supplementary Figure 3) to Eq. (1) results in 
a Km of 0. 35 ± 0. 05 mM, which is within the range of reported values for K-12 NagZ (0. 
31–0. 43 mM) and does not explain the reduced effectiveness of PUGNAc in the 
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cleared lysate [59, 61]. Another E. coli β-N-acetylglucosaminidase with activity for pNP-
GlcNAc could also explain these results, but this hypothesis is ruled-out by the lack of 
activity of the null mutant (Section 3. 4) and by work published previously [60]. Another 
possibility is that the effective concentration of PUGNAc is reduced in the lysate 
compared to the CXC active fraction; other enzymes or cellular material in the lysate 
may sequester or degrade PUGNAc.  
To assess whether inhibition of the E. coli β-N-acetylglucosaminidase increases 
the amount of O-GlcNAc-modified ABL2-FABD produced with the co-expression 
system, PUGNAc was added to the growth media at 0, 1, 2, and 10 µM. The relative 
amount of O-GlcNAc-modified ABL2-FABD produced was determined by normalizing 
the western blot band density to total ABL2-FABD protein using the band density of a 
duplicate SDS-PAGE gel image (Figure 2-4a and b). As shown Figure 2-4c, the amount 
of insoluble, O-GlcNAc-modified ABL2-FABD increases with increasing PUGNAc, 
consistent with an E. coli β-N-acetylglucosaminidase cleaving O-GlcNAc in vivo. Even 
with 10 µM PUGNAc, soluble O-GlcNAc-modified ABL2-FABD is absent (Figure 2-4b). 
This result is consistent with poor inhibition of E. coli β-N-acetylglucosaminidase in the 
cleared lysate with PUGNAc. The possible explanations are the same as discussed in 
the previous paragraph with the additional possibility of inefficient transport into the cell. 
Alternatively, the results suggest that soluble, O-GlcNAc-modified ABL2-FABD is 
unstable. However, the latter is not supported by the fact that the relative levels of 
soluble to insoluble ABL2-FABD (as assessed by SDS-PAGE (Figure 2-4a)) are not 
significantly different even when O-GlcNAc is increased. These results taken together 
indicate that an E. coli enzyme, likely NagZ, cleaves O-GlcNAc from the soluble protein, 
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the enzyme is inhibited by PUGNAc, the effectiveness of PUGNAc inhibition in cleared 
lysate and in vivo is reduced, and the insoluble O-GlcNAc-modified ABL2-FABD is 
protected from the β-N-acetylglucosaminidase activity.  
 
Figure 2-6 The β-N-acetylglucosaminidase activity of cleared lysate with PUGNAc (0, 1, 
2 µM) was measured using the pNP-GlcNAc spectrophotometric assay. The lysate was 
from the co-expression of ABL2-FABD (pET-28b-ABL2-FABD) and OGT (pET43. 1-
OGT) in E. coli BL21-Gold(DE3). Each sample and control were run in triplicate, and the 
error bars represent the standard deviation of these measurements. The 405 nm 
absorbance values were converted to activity (right vertical axis) using the extinction 
coefficient of nitrophenolate.  
2. 3. 3 E. coli NagZ cleaves O-GlcNAc from a peptide 
To determine if E. coli β-N-acetylglucosaminidase can deglycosylate an O-
GlcNAc-modified peptide, the release of GlcNAc from a synthetic O-GlcNAc-modified 
peptide incubated with partially purified E. coli β-N-acetylglucosaminidase was 
monitored with 1H NMR. The α-GlcNAc anomeric 1H signal at 5. 2ppm (Figure 2-7, full 
spectra in Supplementary Figure 4) was monitored for the glycopeptide control, the 
glycopeptide and active fraction mixture, the active fraction control, and the active 
fraction control with 200 µM GlcNAc after incubation at 37 °C for 5 h. No α-GlcNAc was 
detected in the glycopeptide or active fraction control samples (Figure 2-7a and d). α-
GlcNAc was detected in the mixture of glycopeptide and partially purified β-N-
acetylglucosaminidase sample (Figure 2-7c) at a concentration of approximately 40 µM 
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GlcNAc. These results demonstrate that the E. coli β-N-acetylglucosaminidase has 
activity toward this O-GlcNAc-modified peptide, and likely has activity toward O-GlcNAc-
modified proteins in vivo.  
 
Figure 2-7  Fractions from CXC of BL21-Gold(DE3) lysate with β-N-
acetylglucosaminidase activity toward MU-GlcNAc were pooled and tested for β-N-
acetylglucosaminidase activity toward the synthetic O-GlcNAc-modified peptide, 
SVES(β-O-GlcNAc)GSADAK-NH2. (a) CXC fraction control, (b) CXC fraction control 
with 200 µM GlcNAc added, (c) CXC fraction with 200 µM glycopeptide, and (d) 200 µM 
glycopeptide control in CXC buffer. The spectra shown are expanded regions from 5. 1 
to 5. 3 ppm, with a gray dashed line indicating the α-GlcNAc chemical shift (center of 
the doublet). All spectra were processed and expanded identically for direct 
comparison. The full spectra are included in Supplementary Figure 4. The glycopeptide 
control sample (d) has extra noise due to truncation artifacts from the water peak; the 
additional noise is small and does not affect spectral interpretation. Based on the 1H 
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anomeric α-GlcNAc intensity in (b), approximately 40 µM GlcNAc was hydrolyzed by the 
E. coli β-N-acetylglucosaminidase in 5 h at 37 °C (c).  
2. 3. 4 Identifying the E. coli β-N-acetylglucosaminidase as NagZ 
To verify that NagZ is the only β-N-acetylglucosaminidase in E. coli and the 
enzyme purified and characterized in these studies, a K-12 ∆nagZ strain and parent 
strain were tested for β-N-acetylglucosaminidase activity. Cleared lysate from cultures 
were tested for activity using the MU-GlcNAc fluorescence assay (Supplementary 
Figure 5). As expected, activity was detected in the K-12 parent strain. No significant 
activity was found in any of the fractions or the cleared lysate of the K-12 ∆nagZ strain, 
indicating that NagZ is the only β-N-acetylglucosaminidase in E. coli, as Yem and Wu 
also observed [59]. These results confirm that the β-N-acetylglucosaminidase-active 
fractions used in the kinetic assays and NMR experiments must have contained NagZ.  
To determine if NagZ is the only E. coli enzyme with activity toward O-GlcNAc-
modified proteins, lysate from K-12 ∆nagZ strain was incubated with 200 µM O-GlcNAc-
modified peptide and monitored with 1H NMR. Even after 22. 5 h of incubation at 37 °C, 
the 1H spectrum (Figure 2-8c, full spectra in Supplementary Figure 6) did not show any 
detectable α-GlcNAc greater than the limit of quantitation (10 µM). The lack of activity 
toward the glycopeptide indicates that NagZ is the one and only enzyme that sabotages 
the in vivo production of O-linked β-N-acetylglucosamine-modified proteins with E. coli.  
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Figure 2-8 1H NMR spectra of (a) ∆nagZ K12 lysate, (b) lysate with 200 µM GlcNAc, 
and (c) lysate with 200 µM glycopeptide, SVES(β-O-GlcNAc)GSADAK-NH2. All samples 
were incubated at 37 °C for 22. 5 h to test for β-N-acetylglucosaminidase activity toward 
the synthetic O-GlcNAc-modified peptide. The spectra shown are expanded regions 
from 5. 1 to 5. 3 ppm, with a gray dashed line indicating the α-GlcNAc chemical shift 
(center of the doublet). All spectra were processed and expanded identically for direct 
comparison. The full spectra are included in Supplementary Figure 6. Based on the 
signal-to-noise ratio of the 200 µM GlcNAc peak in (b), the limit of quantitation (LOQ) in 
(c) is 10 µM GlcNAc.  
2. 4 Conclusions 
E. coli has not been used to produce milligram quantities of soluble O-GlcNAc-
modified proteins because an endogenous E. coli enzyme, NagZ, removes O-GlcNAc 
from modified proteins in vivo and in vitro. An E. coli co-expression system was 
developed to modify proteins with O-GlcNAc in vivo using human OGT. E. coli is a good 
 44 
host because it lacks endogenous OGT activity, can produce milligram quantities of 
protein, and allows for metabolic labeling with isotopes for NMR structure determination. 
Three substrate proteins were successfully O-GlcNAc-modified with the co-expression 
system: CREB-Q2, CREB-Q2-bZIP, and ABL2-FABD. CREB-Q2 and ABL2-FABD, in 
particular, are soluble proteins, but the O-GlcNAc-modified proteins were only found in 
the insoluble pellet. The O-GlcNAc-modification may cause the substrate proteins to 
become unstable and precipitate; particularly, if the modification is added co-
translationally before the protein has folded. Independent of whether O-GlcNAc causes 
insolubility, several pieces of evidence suggest that E. coli NagZ cleaves O-GlcNAc 
from the soluble substrate protein in vivo and in vitro. The amount of O-GlcNAc-
modified ABL2-FABD produced with the co-expression system increased when a β-N-
acetylglucosaminidase inhibitor, PUGNAc, was added to the growth media. NMR was 
used to show that an E. coli enzyme cleaves O-GlcNAc from an O-GlcNAc-modified 
peptide, a foreign substrate. Even though the E. coli β-N-acetylglucosaminidase was not 
directly identified with mass spectrometry, the lack of β-N-acetylglucosaminidase activity 
in lysate from a K-12 ∆nagZ strain both toward MU-GlcNAc and an O-GlcNAc-modified 
peptide demonstrates that NagZ is the only E. coli β-N-acetylglucosaminidase. 
Moreover, the lack of activity in the knockout confirms that NagZ was present in the 
samples shown to cleave O-GlcNAc and is inhibited by PUGNAc. The Km’s of 
BL21Gold(DE3) NagZ determined, 0. 35 mM pNP-GlcNAc and 5. 6 µM MU-GlcNAc, are 
consistent with values published for K-12 NagZ [59, 61]. The inhibition constant of 
BL21-Gold(DE3) NagZ was determined to be 25. 5 nM and is consistent with V. 
cholerae NagZ, but the mechanism of reduced PUGNAc effectiveness in cleared lysate 
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and in in vivo experiments remains unclear [64]. Efforts are currently underway to test 
the co-expression system in ∆nagZ E. coli strains for increased yields and soluble O-
GlcNAc-modified proteins.  
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Chapter 3:  Is NagZ the saboteur?  
Chapter 3. 1 Introduction 
3. 1. 1 The Hexosamine biosynthesis pathway in E. coli 
UDP-GlcNAc is an important component in E. coli. It is a major precursor of the 
bacterial cell wall. (3)  The enzymes of the hexosamine biosynthesis pathway in E. coli 
are different from those in humans, but the steps of the pathway are similar. Glucose is 
transported into the E. coli cell and phosphorylated by a glucose specific 
phosphotransferase (PstG), and phospho-glucose isomerase (Pgi) interconverts 
glucose-6-phosphate to fructose-6-phospate. Glucosamine-6-phosphate synthase 
(GlmS) transfers an amino group from glutamine to make glucosamine-6-phosphate, 
which is then converted to glucosamine-1-phosphate by phosphoglucosamine mutase 
(GlmM). N-acetylglucosamine-1-phosphate is formed through the acetylation of 
glucosamine-1-phosphate by glucosamine-1-phosphate acetyltransferase (GlmU). 
Finally, N-acetylglucosamine-1-phosphate is uridylated by N-acetylglucosamine-1-
phosphate uridylyltransferase (GlmU) to form uridine diphosphate N-acetylglucosamine 
(UDP-GlcNAc). Glucosamine and N-acetylglucosamine can enter the HBP as well. 
Glucosamine is transported into the cell and phosphorylated by mannose transporter 
(ManXYZ), and N-acetylglucosamine is transported and phosphorylated by NagE, a N-
acetylglucosamine specific transporter. N-acetylglucosamine is deacetylated by N-
aceytglucosamine-6-phosphate deacetylase to glucosamine-6-phosphate where it 
continues along the HBP [66, 67]. N-acetylglucosamine that is cleaved from the cell wall 




Figure 3-1 Glucose, glucosamine, and N-acetylglucosamine are used by E. coli’s 
hexosamine biosynthesis pathway to make UDP-GlcNAc.  
 
3. 1. 2 The role of β-N-acetylglucosaminidase (NagZ) in E. coli 
E. coli is a prokaryotic single cell organism with a cellular membrane made of 
murein also known as peptidoglycan. Peptidoglycan is composed of cross-linked 
alternating GlcNAc-β1,4-MurNAc-peptide monomers [68]. The main function of the 
peptidoglycan layer is to support the cell wall structure and balance the cytoplasm’s 
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osmotic pressure. There are several enzymes that participate in the degradation of the 
peptidoglycan layer. NagZ is the only β-N-acetylglucosaminidase whose function is to 
cleave N-acetylglucosamine (GlcNAc) from N-acetylmuramic acid (MurNAc) peptides 
for peptidoglycan recycling [69].  
 
Figure 3-2  NagZ cleaves the bond between GlcNAc and MurNAc, of the peptidoglycan 
layer [70]. Adapted from: Triassi, A. J. , M. S. Wheatley, M. Savka, H. M. Gan, R. C. J. 
Dobson, and A. O. B. Hudson, L,l-diaminopimelate aminotransferase (dapl): A putative 
target for the development of narrow-spectrum antibacterial compounds. Frontiers in 
Microbiology, 2014. 5.  
GlcNAc, clea:ved from the cell, is recycled to make more UDP-GlcNAc, which is 
a precursor used to make the peptidoglycan. Knocking out nagZ inhibits the cells ability 
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to cleave GlcNAc from MurNAc leading to a build-up of the disaccharide in the 
cytoplasm. nagZ knockout (ΔnagZ) cells have less GlcNAc and UDP-GlcNAc in the 
cytoplasm compared to the wild type [69]. The level of O-GlcNAcylation is dependent 
upon the amount of UDP-GlcNAc [71]. Although a ∆nagZ system for expression of O-
GlcNAc-modified proteins may prevent glycosidase activity, it may be limited in the 
amount of glycoprotein it can produce because of the lower level of UDP-GlcNAc. In this 
chapter we will analyze the effects of ΔnagZ on the expression of O-GlcNAc-modified 
proteins.  
3. 2 Materials and Methods 
3. 2. 1 Materials  
Hen egg white lysozyme, glycerol, glucose (Glc), glucosamine (GlcN), N-acetyl-
D-glucosamine (GlcNAc), O-(2-acetamido-2-dexoy-d-glucopyranosylidene)amino-N-
phenylcarbamate (PUGNAc), sodium lauroyl sarcosinate (sarkosyl), sodium chloride 
(NaCl), sodium phosphate dibasic, sodium phosphate monobasic, 4-(2-hydroxyethyl)-1-
piperazineethanesulfonic acid (HEPES), bromophenol blue, Coomassie brilliant blue 
R250, sodium dodecyl sulfate (SDS), glycine, tris(hydroxymethyl)aminomethane (tris), 
2-mercaptoethanol, imidazole, urea, acetic acid, methanol, and kanamycin were 
purchased from Sigma-Aldrich. Rosetta(DE3)pLysS cells, BugBuster protein extraction 
reagent, and ampicillin were purchased from EMD Millipore/Novagen. A UNO S1 cation 
exchange column, Precision Plus Protein Unstained Standards, 4–20% mini-PROTEAN 
TGX precast gels, immun-blot low fluorescence PVDF membrane, and Laemmli buffer 
were purchased from Bio-Rad. 2-log DNA ladder, 10-beta cells, T4 DNA ligase, NdeI 
restriction enzyme, and XhoI restriction enzyme were purchased from New England 
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Biolabs. BioReagents EZ-Run Rec Protein Ladder, Coomassie (Bradford) Protein Assay 
kit, O-GlcNAc-modified BSA, anti-O-GlcNAc MAb CTD 110. 6, and DyLight 550-
conjugate Goat anti-Mouse IgG secondary antibody were purchased from Thermo 
Scientific/Pierce Antibodies. Luria broth (LB) and agar were purchased from BD 
Biosciences. Wheat germ agglutinin (WGA) agarose and O-GlcNAc-modified BSA were 
purchased from Vector Labs. Other chemicals and materials used include isopropyl β-
D-1-thiogalactopyranoside (IPTG, Affymetrix Anatrace), Ni Sepharose 6 Fast flow (GE 
Healthcare), chloramphenicol (Calbiochem), QIAprep spin miniprep kit (Qiagen), Costar 
96 well UV transparent flat bottom plates, K-12 ∆nagZ knockout strain (JW1093-1) and 
K-12 parent strain (BW25113) (Keio Collection, E. coli Genetic Resources at Yale, 
CGSC, The Coli Genetic Stock Center) [72], and clone HsCD00331895 of the F-actin 
binding domain of Abelson tyrosine-kinase 2 (ABL2-FABD) in pET15 vector (DNASU 
Plasmid Repository, PSI:Biology-Materials Repository) [46]. All water used was supplied 
from a Millipore Direct-Q 3 ultrapure water system.  
3. 2. 2 Knocking out the nagZ gene in the Rosetta(DE3) pLysS strain 
The ∆nagZ Rosetta(DE3)pLysS strain was made by Dr. William Doerrler and Lisa 
Boughner, a graduate student.  
3. 2. 3 Making the ΔnagZ Rosetta(DE3) pLysS cells competent  
Four single ∆nagZ Rosetta(DE3)pLysS colonies were cultured in 5 mL of LB with 
kanamycin (50 µg/ml) and chloramphenicol (35 µg/ml) at 37 oC overnight. These 
cultures were added to 50 mL of fresh LB with the appropriate antibiotics and cultured 
for 3 hr. The cells were cooled on ice for 20 min and spun down at 3,000 g for 15 min at 
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4 oC. The cells were resuspended in 10 mL of 0. 1 M CaCl2 at 4 oC and spun down 
again. The supernatant was removed and the cells were allowed to dry for 1 min. The 
cells were reconstituted in 2 mL of 0. 1 M CaCl2 at 4 oC and stored as 100 µl aliquots for 
transformation.  
3. 2. 4 Transformation 
pCDF-ABL2 and pET43. 1-OGT were transformed into the ΔnagZ 
Rosetta(DE3)pLysS competent cells using a heat shock method. A mixture of 1 µl  of 
each plasmid and 100 µl of the competent cells was heat shocked at 42 oC for 45 s. The 
cells were immediately chilled on ice for 2 min and incubated with shaking for 1 hr at 37 
oC. ΔnagZ Rosetta(DE3)pLysS colonies with pCDF-ABL2 and pET43. 1-OGT were 
grown on LB agar with 50 µg/mL spectinomycin, 100 µg/mL ampicillin, 50 µg/mL 
kanamycin, and 35 µg/mL chloramphenicol.   
3. 2. 5 Expression conditions 
ABL2 and OGT were co-expressed in ΔnagZ Rosetta(DE3)pLysS cells. Three 
colonies of ΔnagZ Rosetta(DE3)pLysS with pCDF-ABL2 and pET43. 1-OGT were 
cultured overnight at 37 oC in 150 mL of LB with the appropriate antibiotics. 1 mL of the 
overnight culture was used to inoculate fresh LB or minimal media (see Table 3-1 for 
minimal media expression recipe) with the appropriate antibodies at 37 oC. Once the 
cultures reached an OD600 of 0. 6-0. 8, they were divided into three 50 mL aliquots and 
induced with 50 µL of 0. 5 M IPTG. Each 50 mL aliquot was incubated at 16 oC, 23 oC, 
and 37 oC for 16 hr, 12 hr, and 3 hr, respectively. The cells were harvested by 
centrifugation at 3000 g for 15 min at 4 oC. The supernatant was discarded, and the 
 52 
pellet was reconstituted with 1 mL of BugBuster. The suspended cells were sonicated 
using a Sonics Vibra-cell VCX130 at 30% power for 120 s (3 cycles of 30 s on/10 s off). 
The lysed cells were spun down at 30,000 g for 30 min at 4 oC. The cleared lysate was 
separated from the pellet and saved for nickel affinity chromatography. The expression 
procedure was performed for pCDF-ABL and pETDuet-1-codon optimized OGT co-
expression in ΔnagZ Rosetta(DE3)pLysS.  
Table 3-1 The recipe for 1 L of minimal growth media, 1 L of 10X M9 salts, and 100 mL 
of 1000X trace mineral. 
 
10X M9 salts  100. 0 ml 
D-glucose stock (20 g/100 ml) (0. 2 µm filter sterilized) 20. 0 ml 
1000X Trace minerals 1. 0 ml 
1 M MgCl2 (autoclaved) 2. 0 ml 
50 mM CaCl2 (autoclaved) 2. 0 ml 
Vitamin Solution (1 tablet/20 ml) (0. 2 µm filter sterilized) 2 ml 
 
10X M9 salts (autoclaved) 
Na2HPO4•7H2O 128 g 
KH2PO4 30 g 
NaCl 5 g 
NH4Cl 10g 
 
1000X Trace Minerals (10 mM each) (autoclaved) 
FeCl3•6H2O 0. 2703 g 
CuSO4•5H2O 0. 2497 g 
MnSO4•6H2O 0. 1690 g 
ZnSO4•6H2O 0. 2875 g 
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3. 2. 6 Ni-affinity purification conditions 
Ni Sepharose 6 Fast Flow with a binding capacity of 40 mg/mL was used in 0. 1 
mL aliquots. The nickel media was placed in microspin columns and centrifuged at 300 
g to remove the storage buffer. Water was used to rinse the media, followed by 1 mL of 
wash buffer (50 mM phosphate, 150 mM NaCl, and 20 mM imidazole at pH 8) to 
equilibrate the media. The cleared lysate was added to the equilibrated media and 
allowed to flow through by gravity. The media was washed with 2 mL of wash buffer. 
The protein of interest was eluted using 200 µL of elution buffer (50 mM phosphate, 150 
mM NaCl, and 300 mM imidazole at pH 8).  
3. 2. 7 SDS-PAGE and western blot analysis 
The cleared lysate and insoluble pellet were analyzed with SDS-PAGE and 
western blot analysis. The cleared lysate was diluted in a 1:5 ratio with BugBuster or 
SDS-PAGE buffer. 20 μL of the dilute cleared lysate was added to 20 μL of Laemmli 
sample buffer. The samples were divided in half to run on two different gels. Purified 
samples were prepared as 30 μL aliquots in a 1:1 ratio with Laemmli buffer. These 
samples were also divided for two different gels: one gel was stained with Coomassie 
brilliant blue R-250 stain, and the other gel was prepared for O-GlcNAc detection by 
western blot analysis. All samples were boiled for 15 min before loaded onto a 4-20% 
tris protein gel. The protein gels were run in buffer (25 mM tris, 192 mM glycine, and 0. 
1% SDS) at 120 V for 1 hr.  
Western blot detection of O-GlcNAc was performed by transferring the proteins 
from the gel to a PVDF-membrane in transfer buffer (25 mM tris, 192 mM glycine, and 
10% methanol) using a Bio-Rad transfer electrophoresis system at 120 V for 3 hr. Anti-
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O-GlcNAc MAb CTD 110. 6, an O-GlcNAc specific antibody, in combination with 
DyLight 550-conjugate Goat anti-Mouse IgG, a secondary antibody conjugated to a 
fluorescent tag, was used to probe the blot for detection of O-GlcNAc. The membranes 
were first blocked using 1X BSA blocking buffer (25 mM sodium phosphate,150 mM 
NaCl, 0. 1% tween and 1% BSA at pH 7. 4) for 1 hr at room temperature. Anti-O-
GlcNAc antibody and fresh BSA blocking buffer in a 1:5000 dilution were added to the 
blot and incubated at room temperature for 1 hr. The blot was rinsed with PBST buffer 
(25 mM sodium phosphate, 150 mM NaCl, and 0. 1% tween at pH 7. 4) three times for 5 
min each. The secondary antibody was added to fresh 1X BSA blocking buffer and 
incubated at room temperature for an additional hour. The blot was rinsed a final time 
and imaged using a GE Typhoon 9410 imager. The fluorescent secondary antibody was 
excited at 532 nm and detected between 565-595 nm using a 580 nm filter.  
3. 2. 8 WGA agarose affinity chromatography 
The nickel purified samples were exchanged into WGA wash buffer (20 mM 
HEPES, 150 mM NaCl at pH 8) using Amicon centrifugal filter units with a molecular 
weight cut-off of 10 kDa to remove the imidazole. The WGA agarose was divided into 
100 µL aliquots and washed with 1 mL of wash buffer. The sample was incubated with 
the WGA agarose for 20 hr at 4 oC. The mixture was then transferred to a microspin 
column and centrifuged at 300 g for 1 min. The agarose was washed with 1 mL of wash 
buffer, incubated with 200 µL of WGA elution buffer (20 mM HEPES, 150 mM NaCl, 500 
mM GlcNAc at pH 8) for 30 min at 4 oC, and centrifuged again to collect the elution.  
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3. 2. 9 Coomassie protein concentration assay 
Nickel-purified and WGA-separated samples were exchanged into WGA wash 
buffer using Amicon centrifugal filter units with a molecular weight cut-off of 10 kDa. 
Aliquots (10 µL) aliquots were saved for Coomassie analysis. BSA standards were 
prepared in WGA wash buffer at 0, 10, 20, 40, 50 μg/mL. Standards and samples were 
prepared in 50 μL aliquots. Samples were tested and prepared within the linear range 
based on visual inspection. The flow-through and eluents from the WGA purification 
were analyzed using a Biotek PowerWave XS microplate spectrophotometer at 595 nm.  
3. 2. 10 Supplementing ∆nagZ E. coli cultures with sugar 
pCDF-ABL2 and pET43. 1-OGT were transformed into ∆nagZ 
Rosetta(DE3)pLysS competent cells and selected on LB agar with spectinomycin, 
ampicillin, kanamycin, and chloramphenicol, as previously described. A colony known to 
express ABL2 and OGT well was cultured in MM in the presence 0. 5% glucose, 
glucosamine, or N-acetylglucosamine in addition to the 0. 4% glucose already in the 
MM. At an optical density at 600 nm of 0. 6-0. 8, the cultures were induced with 0. 5 mM 
IPTG and grown for 16 hr at 22-25 oC. The cells were harvested using BugBuster 
protein extraction reagent and lysed with 3 freeze/thaw cycles and ultrasonication. 
Cleared lysate was prepared by centrifugation at 30,000 g for 30 min at 4 oC. Ni 
Sepharose 6 Fast Flow, a nickel affinity media, was used to purify the His-tagged ABL2 
protein. Gravity flow was used to ensure maximum binding. The nickel affinity media 
was equilibrated with wash buffer. The cleared lysate was loaded onto 200 µL of media. 
The media was then washed with 2 mL of buffer and the protein was eluted with 1 mL of 
300 mM imidazole elution buffer.  
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3. 2. 11 Resolubilized O-GlcNAc-modified ABL2 
The insoluble portion of the cell lysates were dissolved in 1 mL of 10% sodium 
lauroyl sarcosinate (sarkosyl), followed by dilution to 1% sarkosyl with water and 
ultrasonication at 30% for 120 s (3 cycles of 30 s on/10 s off). The resolubilized protein 
was centrifuged at 30,000 g for 30 min to pellet any remaining insoluble material and 
purified using nickel affinity chromatography as previously described.  
3. 2. 12 OGT activity assay 
ΔnagZ Rosetta(DE3)pLysS with pCDF-ABL2 and pET43. 1-OGT and ΔnagZ 
Rosetta(DE3)pLysS with pCDF-ABL2 with pETDuet-1-codon optimized OGT were 
expressed for 3 hr at 37 oC. The cells were spun down at 3000 g for 10 min at 4 oC. The 
cells were resuspended in 50 mM tris and ultrasonicated at 30% for 120 s (3 cycles of 
30 s on/10 s off). The lysate was separated from the cells by centrifuging at 30,000 g for 
10 min. 1 mM UDP-GlcNAc, 2 μM phenylmethylsulfonyl fluoride (PMSF), 75 units of 
shrimp alkaline phosphatase, and 12. 5 mM magnesium chloride were added to the 
lysates and incubated at 20 oC for 1 hr. The mixtures were analyzed by SDS-PAGE and 
western blot to determine the relative activity of OGT and codon-optimized OGT. In 
addition to O-GlcNAc detection, OGT was detected using Anti-O-GlcNAc Transferase 
(DM-17) produced in rabbits and DyLight 650-conjugate Goat anti-Rabbit IgG.  
3. 3 Results 
3. 3. 1 Expression of O-GlcNAc-modified ABL2 in ΔnagZ E. coli 
pET43. 1-OGT and pCDF-ABL2 were co-expressed in ΔnagZ 
Rosetta(DE3)pLysS using LB media at 16 oC. Figure 3-3a shows the SDS-PAGE of the 
soluble purified ABL2 at a molecular weight of about 14 kDa. Once purified proteins 
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began to precipitate. The precipitated proteins were also analyzed by SDS-PAGE, 
Figure 3-3a shows the precipitated protein, referred to as insoluble. ABL2 purified at pH 
6 did not produce precipitate or ABL2. Figure 3-3b shows the western blot 
corresponding to these samples. The O-GlcNAc-modified ABL2 was only in the 
insoluble sample.  
ABL2 was expressed in abundance, but the purification was poor and once 
purified, it was unstable. The O-GlcNAc-modified ABL2 selectively precipitated with 
many other proteins. The instability is attributed to purification at high pH (> than 8. 5). 
Even though glycosylated ABL2 was temporarily soluble, the amount of O-GlcNAc-
modified protein produced was similar to the wild type expressions. ABL2 was purified 
at a lower pH in an attempt to stabilize the glycoprotein. However, lowering the pH to 6 
hindered the lysis and purification of ABL2.  
 
Figure 3-3 O-GlcNAc-modified ABL2 expressed in the ∆nagZ system was unstable and 
O-GlcNAc-ABL2 selectively precipitated. The soluble and insoluble samples both 
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contain ABL2 as seen on the protein gel (a); however, the western blot (b) shows that 
O-GlcNAc-modified ABL2 seems to be exclusively in the pellet.  
3. 3. 2 ΔnagZ Rosetta(DE3)pLysS sugar trials 
pET43. 1-OGT and pCDF-ABL2 were co-expressed in ΔnagZ 
Rosetta(DE3)pLysS using minimal media (MM) at 22 oC. Glucose, glucosamine, N-
acetylglucosamine or PUGNAc were added to the MM cultures. The soluble lysate and 
the insoluble pellets were analyzed by SDS-PAGE and western blot. Figure 3-4a shows 
the SDS-PAGE analysis of cleared lysate, where the asterisk indicates the expression 
of ABL2. The corresponding western blot (Figure 3-4b) does not show any glycosylation 
for the samples with additional sugar. However, there is a small amount of glycoprotein 
in the control sample. Figure 3-4c shows the SDS-PAGE analysis of the insoluble pellet. 
The western blot (Figure 3-4d) shows an increased amount of glycoprotein in the 
glucose and glucosamine supplemented expressions, compared to the control. The 
addition of PUGNAc also increased the amount of glycoprotein expressed. However, 
ABL2 expressed in the presence of N-acetylglucosamine produced glycoprotein 
comparable to the control.  
Glucose, glucosamine, and N-acetylglucosamine were added to the culture 
media in an attempt to compensate for the possible decrease of UDP-GlcNAc caused 
by knocking out nagZ. These monosaccharaides were selected because they 
participate in the hexosamine biosynthesis pathway. The cultures were grown in MM to 
control the sugar composition and concentration in the media. The soluble lysate and 
the insoluble pellets were analyzed by SDS-PAGE and western blot. As previously 
observed, little or no glycoprotein was present in the lysate of the cultures (Figure 3-4a). 
MM cultures with extra glucose and glucosamine had the highest amount of 
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glycosylation observed thus far. In contrast, the addition of N-acetylglucosamine had no 
effect on the expression of glycoprotein. The cells with N-acetylglucosamine grew four 
times faster than the cultures with the other sugars and minimal media alone. The 
accelerated growth and insubstantial change in glycosylation may be attributed to N-
acetylglucosamine’s ability to up-regulate nagA and nagB, which promote glycolysis 
[73]. Glycolysis is a process where E. coli uses sugars (mainly glucose) to make ATP, 
which is required for maintenance and reproduction of the cells [74]. The addition of 
PUGNAc also increased the amount of glycosylation, suggesting the presence of a 
second glycosidase with activity toward O-GlcNAc-modified proteins in E. coli.  
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Figure 3-4   Analysis of sugar supplemented expression of O-GlcNAc modified ABL2. 
The cleared lysate from cultures supplemented with glucose have a small amount of 
ABL2 (a) that is not glycosylated (b). The pellets corresponding to these samples 
contain about the same amount of ABL2 (c); however, the samples supplemented with 
glucose and glucosamine have an abundance of O-GlcNAc-modified ABL2 (d). The 
pellets containing PUGNAc express more ABL2 (c), but less O-GlcNAc-modified ABL2 
compared to the glucose and glucosamine samples (d).  
 
3. 3. 3 Resolubilized ABL2 
The insoluble glycoprotein from Figure 3-4d was solubilized using detergent and 
isolated from insoluble content and cell debris using nickel affinity chromatography. 
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Figure 3-5a shows the SDS-PAGE analysis of purified resolubilized ABL2. There were 
very small amounts of ABL2 and some other proteins observed. The western blot 
(Figure 3-5b) shows that these results were similar to previous results. The glucose, 
glucosamine, PUGNAc, and PUGNAC+glucose samples had higher levels of 
glycosylation than the control and N-acetylglucosamine sample.  
The overall goal of this project is to express milligram quantities of soluble O-
GlcNAc-modified protein for NMR analysis. In an effort to solubilize O-GlcNAc-modified 
ABL2 without denaturing the protein, sarkosyl was used to solubilize any protein from 
the inclusion bodies. The results were similar to the previous experiments:  glucose and 
glucosamine appeared to have more glycoprotein than both the control and the N-
acetylglucosamine sample. The glucose in combination with PUGNAc appeared to have 
the highest level of purified O-GlcNAc-modified ABL2. The asterisks in Figure 3-5b 
indicate multiple O-GlcNAc-modified ABL2 bands that migrate differently in the SDS-
PAGE gel. More than one O-GlcNAc modification can occur on ABL2, so the bands may 
correspond to different numbers of O-GlcNAc residues. There are a few proteins that 
consistently co-purify with ABL2, suggesting that O-GlcNAc-modified ABL2 may be 
bound to or tightly associated with these proteins.  
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Figure 3-5 Purification of resolubilized O-GlcNAc-modified ABL2. The pellets were 
resolublized with 10% sarkosyl, diluted to 1%, and purified with nickel affinity 
chromatography. The results were very similar to previous data—there is not an 
abundance of ABL2 on the protein gel, (a) yet it is highly glycosylated (b).  
 
3. 3. 4 Optimized expression of O-GlcNAc-modified ABL2 in ∆nagZ 
Previous experiments produced highly glycosylated protein (Figure 3-4d) that 
was insoluble. This glycoprotein can be isolated from the pellet using a sarkosyl. 
Although the detergent experiments worked, it is not clear whether sarkosyl will affect 
the protein’s structure. In an effort to optimize the expression, for the production of 
soluble O-GlcNAc-modified ABL2, the cells were cultured in different conditions. There 
are many variables that can greatly affect the expression of soluble target protein. The 
cells were cultured in a tissue culture flask at slower revolutions per minute (rpm). The 
flat tissue flask doubled the surface area of aeration. These expressions were done at 
room temperature (22-25 oC) instead of a controlled temperature of 22 oC for 18 hrs. 
The expressions were induced with IPTG at an OD600 of 1. 0, instead of 0. 6. Most 
importantly, 10 μM PUGNAc was added to all of the purification buffers. The samples 
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were purified and concentrated for analysis. The sample with 0. 5% glucose was the 
only sample that showed significant amounts of pure, soluble O-GlcNAc-modified 
protein (Figure 3-6). Although the overall expression of ABL2 appears to be low, the 
ratio of glycoprotein to naked protein was high. In contrast to expression in wild type E. 
coli, O-GlcNAc-modified ABL2 expressed in ∆nagZ E. coli remained glycosylated in the 
presence of PUGNAc after several days. O-GlcNAc-modified ABL2 expressed in the 
wild type, in the presence of 10 μM PUGNAc lost the modification after 2 days. It is not 
clear whether the decreased amount of ABL2 is real or if the glycosylation disrupts the 
binding of the coomassie G-250 dye, used for detection of protein. Coomassie is also 
the reagent used in protein concentration assays, and is not compatible with high levels 
of GlcNAc.  
 
Figure 3-6  Optimized expression of soluble O-GlcNAc-modified protein. A starter 
culture from a single colony was used to inoculate sugar-supplemented cultures in MM. 
The expression conditions were optimized to produce soluble O-GlcNAc-modified 
protein. The soluble lysate was purified and concentrated for SDS-PAGE and western 
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blot analysis. The glucose sample was the only sample to produce a substantial amount 
of soluble O-GlcNAc-modified protein.  
3. 3. 5 Comparison of OGT activity produced from human OGT (hOGT) and 
codon-optimized OGT (coOGT) 
The human OGT sequence contains 52 rare codons. Rare codons are DNA 
codons that have a low amount of corresponding tRNA, required for protein synthesis, 
in E. coli. The OGT sequence was codon optimized, cloned into pETDuet-1 by the 
protein facility at LSU, and overexpress in E. coli. Although codon optimized OGT over-
expressed in ∆nagZ E. coli, it did not show any glycosylation, even when glucose and 
glucosamine were added as supplements to the media. To verify that the coOGT was 
active, cleared lysate containing coOGT was used to glycosylate ABL2 in vitro, and the 
relative amount of glycosylation was compared to hOGT in vitro glycosylation. Figure 3-
7 shows the SDS-PAGE and western blot of the in vitro glycosylation reaction. There is 
more coOGT than hOGT and there is more O-GlcNAc-modified protein produced from 
the hOGT reaction. A comparison of the relative band densities of the western blot 
bands to the corresponding SDS-PAGE band for the in vitro coOGT and hOGT 
reactions show that the extent of glycosylation is similar for both enzyme. The same 
cleared lysate was analyzed to assess the relative concentrations of OGT. coOGT was 
more abundant than hOGT. In theory more coOGT should produce more O-GlcNAc-
modified protein, but it does not. These results suggest that coOGT is not as active as 
hOGT, likely because it does not fold properly during translation.  
 65 
 
Figure 3-7 Comparison of human OGT and codon optimized OGT. Anti-O-GlcNAc 
transferase was used to detect the amount of OGT present in the in vitro reaction. Anti-
O-GlcNAc was used to detect the amount of O-GlcNAc-modified protein produced from 
the reaction.  
3. 4 Conclusion  
The ΔnagZ Rosetta(DE3)pLysS E. coli co-expression system produced more O-
GlcNAc-modified ABL2 compared to wild type Rosetta(DE3)pLysS E. coli, but only 
when the media was supplemented with extra glucose or glucosamine. The insolubility 
of O-GlcNAc-modified ABL2 was a problem for both E. coli strains, providing more 
evidence that co-translational modification with O-GlcNAc disrupts ABL2 folding. 
Another possibility is that a second glycosidase is removing O-GlcNAc from soluble 
ABL2. Evidence for this hypothesis includes increased levels of O-GlcNAc-modified 
ABL2 when PUGNAc is added to cultures of ΔnagZ Rosetta(DE3)pLysS E. coli co-
expressing OGT and ABL2. Since O-GlcNAc-modified ABL2 is available in the pellet, 
resolubilized O-GlcNAc-modified ABL2 may be available in sufficient quantities for NMR 
analysis. Another possible solution to producing O-GlcNAc-modified protein in sufficient 
quantities for NMR analysis is to switch the target protein to one that has been modified 
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with in vivo methods. David Vocadlo has had great success with tau and it is biologically 
relevant. [24] 
In vitro glycosylation could be a viable method to produce mg quantities of O-
GlcNAc-modified protein. In the past, in vitro glycosylation has not been efficient, but 
NagZ may have contributed to this apparent inefficiency. The ∆nagZ E. coli may allow 
for in vitro glycosylation without the need for β-N-acetylglucosaminidase inhibitors. 
Optimizing the expression of human OGT is also very important. Increasing the amount 
of hOGT expressed, while maintaining its activity, should increase the amount of protein 
being glycosylated in the lysate. Partial codon optimization may lead a properly folded, 
active, and abundant OGT. Rosetta cells contain tRNA for 6 common rare codons. 
There are 52 rare codons in the hOGT sequence, Rosetta compensates for all but 10. 
These 10 codons are all CGA. Mutating these codons, without changing the amino acid 
may lead to more protein expression.  
Wheat germ agglutinin is often used to enrich O-GlcNAc-modified proteins, but it 
is expensive and is not always efficient because of its weak affinity for terminal GlcNAc. 
In a situation where there is only a very small percent of O-GlcNAc-modified protein, 
enrichment is important for down-stream analysis like mass spectrometry and NMR. 
Galactosyltransferase adds a galactose to O-GlcNAc. This enzymatic process has been 
used to detect O-GlcNAc. While the addition of functionalized galactose provides other 
ways to analyze the modification. The functionalized galactose has a reactive group that 
can be used to bind biotin for enrichment with streptavidin [75]. The addition of a mass 
tag, such as polyethylene glycol (PEG) has been used to visualize multiple-O-GlcNAc-
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modified proteins by SDS-PAGE gel and could be used to give valuable information 
such as how much of the protein is O-GlcNAc-modified and to what degree [33].  
While there is still some optimization required for the co-expression system to 
produce mg quantities of soluble O-GlcNAc-modified protein, there are some promising 
opportunities that need to be explored. The resolubilized samples are highly 
glycosylated and the structures of these proteins should be analyzed. If they are 
properly folded, they may lead to an NMR structure. Even with small amounts of 
resolubilized O-GlcNAc-modified protein, mass spectrometry can be used to map the O-
GlcNAc sites to specific residues. This information alone can provide valuable insight 
into the role of O-GlcNAc in the structure and function of proteins.  
  
 68 
Chapter 4: Chlamydia trachomatis CT663: Structure and Ligand 
Interaction Model 
4. 1 Introduction 
4. 1. 1 Chlamydia trachomatis 
Chlamydia is the most common sexually transmitted bacterial disease in the 
United States [76]. There are 2. 8 million new infections annually [77]. Chlamydia can 
cause reproductive health complications such as pelvic inflammatory disease, infertility 
and ectopic pregnancy. It can also cause neonatal conjunctivitis and pneumonia [78]. 
The disease is asymptotic in 50-80% of patients, so they are often unaware of the 
infection [79]. The rate of re-infection is alarmingly high [80]. Although Chlamydia is both 
curable and preventable, there is a need for better therapies. In 2000, three chlamydial 
strains in clinical patients demonstrated multi-drug resistance to doxycycline, 
azithromycin, and ofloxacin [79].  
Chlamydia is an obligate intracellular bacteria, which means it requires a host cell 
for replication. It infects columnar epithelial cells, which are found in the uterus, the 
respiratory tract, and the eye. The disease manifests in these areas as a urogenital 
infection, pneumonia, and conjunctivitis, respectively. The developmental cycle is 
unique and consists of two alternating cellular forms. The infectious form, elementary 
bodies (EB), attach to host cells and initiate the developmental cycle, after endocytosis 
[81]. The EBs develop into the noninfectious replication form called reticulate bodies 
(RB). These RBs reorganize in an asynchronous manner and then revert back to EBs. 
The now multiplied EBs exit the host cells, lysing the cells in the process [82]. The 




Figure 4-1  Developmental cycle of Chlamydia. Brunham, R. C. ; Rey-Ladino, J. , 
"Immunology of Chlamydia infection: Implications for a Chlamydia trachomatis vaccine," 
Nature Reviews Immunology 2005, 5 (2), 149-161.  
4. 1. 2 Type III secretion 
The elementary bodies use the virulence associated type III secretion system 
(T3SS) to infect the host cells. The T3SS is used by gram-negative bacterial pathogens 
to deliver virulence factors, molecules essential for the induction of infection, into the 
cytosol of host cells [3]. Virulence factors can be a wide variety of molecules, and are 
usually on the bacterial surface or secreted from the pathogen. Because the molecules 
are critical for the initiation and replication of the disease, they are sensible targets for 
drug development [83]. The T3SS is composed of an injectisome, an ATPase, 
translocator molecules, effector molecules, and chaperones [84]. The injectisome is the 
major machinery of the virulence T3SS. It is a multi-protein complex that consists of a 
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basal body embedded within the bacterial membrane topped by a needle-like structure 
[85]. It serves as a channel through which proteins reach the host cell. Proteins are 
secreted through the injectisome by an ATP consuming process, using ATPases 
located in the bacterial cytosol [84]. Translocator proteins are secreted to form the 
translocon, which sits at the needle-like end of the injectisome. The translocon 
physically links the injectisome to the host cell, enabling secretion of virulence factors 
into the host cell.   
 
Figure 4-2 Diagram of animal pathogenic bacterial T3SS similar to that of Chlamydia 
[86]. Büttner D , and He S Y Type III Protein secretion in plant pathogenic bacteria. 
Plant Physiology. 2009;150:1656-1664.  
The secreted virulence factors consist of effector and chaperone proteins. 
Effectors are eukaryotic-like proteins that modulate the host cell throughout the 
infectious cycle. Bacterial pathogens secrete effectors that manipulate the actin 
cytoskeleton of the host cell, which enables remodeling of the membrane in order to 
promote uptake or adhesion of the bacteria [84]. Effectors and translocators are often 
bound to chaperones in the bacterial cytosol. Chaperones are proteins that bind to 
virulence factors in order to keep them in secretion-competent state as they travel from 
the bacteria and through the injectisome. The chaperones also prevent aggregation and 
premature interaction of virulence factors, as well as regulate transcription of T3SS 
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genes [87]. T3SS chaperones can be categorized into three classes based on structure 
and substrate similarity. Class I chaperones are approximately 130 residues. Class IA 
chaperones associate with only one effector, while those in class IB associate with 
multiple effectors. Both sub-classes of class I adopt homo-dimeric structural folds. Class 
II chaperones are approximately 160 residues and associate with translocator proteins. 
They are structurally distinct, typically containing three tetratricopeptide repeats (TPR) 
[84, 88]. Class III chaperones are extra-cellular filament proteins that have extended 
alpha helical structure.  
4. 1. 3 CT663/Scc1-CopN complex 
CT663 is a class 1A chaperone found in Chlamydia trachomatis. It is a dual 
function enzyme; it functions as a chaperone and as a transcription factor that regulates 
the global transition from RB to EB in the Chlamydial developmental cycle. CT663 
carries out this function by associating with the β subunit (RpoB) and the primary sigma 
subunit σ66 (RpoD) of Chlamydial RNA polymerase (RNAP). This association inhibits σ66 
dependent transcription [89]. Analysis of CT663 as a chaperone has shown that it 
interacts with secretion substrates as well as another class IA T3SS chaperone, Scc1 
[84]. This interaction suggests that CT663 and Scc1 form a heterodimeric chaperone 
complex. The Ct663/Scc1 complex binds Chlamydial outer protein N (CopN), a T3SS 
effector that is essential for virulence. CopN destroys microtubules in cytoskeleton 
networks, resulting in cell cycle arrest. CopN is also a T3SS plug protein [90]. Plug 
proteins typically block the secretion pore, allowing protein export only in the presence 
of a currently unknown extracellular signal [84]. Although the formation of a CT663, 
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Scc1, and CopN complex has been confirmed, the order of binding events and 
arrangement are unknown.  
4. 1. 4 Research goal 
The goal of this research is to determine the structure and analyze the ligand 
interactions of CT663. Analysis of CT663’s interactions with σ66, β-subunit, Scc1, and 
CopN will provide information about how CT663 functions as a dual enzyme. Structural 
analysis of CT663 and its binding partners will provide a rational drug model. 
Knowledge of how these proteins interact will facilitate the design of a small molecule 
that inhibits key interactions necessary for infection. An x-ray crystallographic structure 
of CT663 has been attempted by David Worthylake, a collaborator at LSU Health 
Science Center School of Medicine, but crystal formation has not been successful. 
Nuclear magnetic resonance (NMR) spectroscopy will be used to determine the 
structure of the chaperones CT663 and Scc1, as well as the chaperone complex 
CT663/Scc1. Structural determination of any of the chaperones bound to the effector 
CopN is not feasible, due to size constraints. NMR can still provide information about 
these interactions, such as which residues participate in binding and how binding affects 
the structure of the chaperones. Further binding analysis will be done using surface 
plasmon resonance (SPR) spectroscopy to determine the binding kinetics and 
arrangement of CT663, Scc1, and CopN.  
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4. 2 Materials and Methods  
4. 2. 1 Materials  
Glycerol, glucose, sodium chloride (NaCl), sodium phosphate dibasic, sodium 
phosphate monobasic, 2-(N-morpholino)ethanesulfonic acid (MES), ammonium acetate, 
dithiothreitol (DTT), ethylenediaminetetraacetic acid (EDTA), bromophenol blue, 
Coomassie brilliant blue R250, sodium dodecyl sulfate (SDS), glycine, 
tris(hydroxymethyl)aminomethane (tris), 2-mercaptoethanol, imidazole, urea, acetic 
acid, methanol, kanamycin, ampicillin, and chloramphenicol were purchased from 
Sigma-Aldrich. Rosetta(DE3)pLysS cells, BugBuster protein extraction reagent, 3K and 
10K Amicon centrifugal filters, and ampicillin were purchased from EMD 
Millipore/Novagen. Precision Plus Protein Unstained Standards, 4–20% mini-PROTEAN 
TGX precast gels, and Laemmli buffer were purchased from Bio-Rad. BioReagents 
glutathione agarose, HRV 3C protease, EZ-Run Rec protein ladder, and Coomassie 
(Bradford) protein assay kit were purchased from Thermo Scientific/Pierce Antibodies. 
Luria broth (LB) and agar were purchased from BD Biosciences. Hiprep 16/60 
Sephacryl-S-100 HR and Ni Sepharose 6 Fast flow were purchased from GE 
Healthcare. Other chemicals and materials used include isopropyl β-D-1-
thiogalactopyranoside (IPTG, Affymetrix Anatrace), deuterium oxide (D2O, Cambridge 
Isotopes), tween 20 (Fisher), chloramphenicol (calbiochem), QIAprep spin miniprep kit 
(Qiagen), Costar 96 well UV transparent flat bottom plates were also purchased.  
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4. 2. 2 Structure predictions  
The amino acid sequence of CT663, Scc1, and CopN were submitted to an 
online protein homology/analogy recognition engine version 2. 0 (Phyre2) for structure 
prediction.  
4. 2. 3 CT663 expression and purification  
  pET21-CT663 was transformed into Rosetta (DE3)pLysS competent E. coli cells 
and plated on Luria broth (LB) agar with 100 µg/mL ampicillin and 35 µg/mL 
chloramphenicol. Single colonies were selected for inoculating 5 mL of LB as starter 
cultures and grown overnight at 37 oC with a shaking speed of 250 revolutions per 
minute (rpm). The starter culture was added to 0. 5 L of LB media and grown at 37 oC 
with 250 rpm. Once the culture reached an OD600 of 0. 6-0. 8, it was induced with 0. 5 
mM IPTG. The culture grew at 37 oC for 3 hr and the cells were harvested at 4,000 g for 
10 minutes at 4 oC. The cells were reconstituted in 10 mL of BugBuster followed by 
ultrasonication at 30% power for 120 s (3 cycles of 30 s on/10 s off) using a Sonics 
Vibra-cell VCX130. Cleared lysate was prepared by centrifugation at 30,000 g for 30 
min at 4 oC. CT663 was purified from the cleared lysate using 1 mL of Ni Sepharose 6 
fast flow media by gravity flow. CT663 was washed with 20 mL of 20 mM sodium 
phosphate, 300 mM NaCl, 20 mM imidazole, pH 8 buffer and eluted in 10 mL of buffer 
with 300 mM imidazole.  
4. 2. 4 CT663 and Scc1 co-expression and co-purification:   
E. coli cells containing pACYC184-Scc1-6XHis and pET28-CT663 were sent to 
us by our collaborator, Dr. Li Shen, at the LSU Health Science Center School of 
Medicine. The cells were plated on LB agar with 35 µg/mL chloramphenicol and 50 
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µg/mL kanamycin. 5 mL starter cultures were grown from single colonies. The starter 
culture was added to 0. 5 L of LB media at 37 oC. Once the culture reached an optical 
density of 0. 6-0. 8 at 600 nm, they were induced with 0. 5 mM IPTG and 0. 2% 
arabinose. The cells were harvested and the Scc1:CT663 complex was co-purified 
following the same procedures used for CT663 (see section 4. 2. 1).  
4. 2. 5 CopN expression and purification  
E. coli cells containing pGEX098-CopN were sent to us by our collaborator, Dr. Li 
Shen, at the LSU Health Science Center School of Medicine. The cells were plated on 
LB agar with 100 µg/mL ampicillin. The cells were grown and harvested following the 
same procedures used for CT663 (see section 4. 2. 2). CopN was purified using 1 mL of 
glutathione agarose media by gravity flow. The media was equilibrated with 10 mL of 50 
mM tris, 150 mM NaCl, pH 8 buffer (TBS). The cleared lysate was added to the media 
and gently mixed at 4 oC for 30 min. The media was washed with 20 mL of TBS. The 
GST-fusion tag was cleaved from CopN using 20 units of HRV 3C protease in 2 mL of 
TBS with gently mixing at 4 oC for 16 hr. The flow-through containing CopN and HRV 3C 
was collected, and HRV 3C was removed by passing the sample over 0. 5 mL of nickel 
affinity media.  
4. 2. 6 Separation of CT663 and Scc1  
Previous research indicates that Scc1 is insoluble when expressed alone. 
However, when it is co-expressed with CT663, it forms a soluble complex. The 
CT663/Scc1 complex was expressed and purified as previously described. 6M urea, 8M 
urea, 2% SDS and 1% sarkosyl were used to separate the complex. Fast protein liquid 
chromatography (FPLC) was used to bind the complex to nickel media. The media was 
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washed with wash buffer containing one of the separating agents. Any remaining bound 
protein was eluted with 20 mM sodium phosphate, 300 mM NaCl, and 300 mM 
imidazole at pH 8 buffer. The UV absorbance was monitored for the release of protein 
during the separation wash. SDS-PAGE was used to analyze the proteins that eluted 
after separation.  
4. 2. 7 Gel electrophoresis analysis  
Purified CT663, Scc1/CT663 complex, and CopN were run in 4-20% tris-HCl gels 
under denatured and native conditions. The denatured samples were prepare in a 1:1 
ratio with Lammeli buffer containing 5% v/v 2-mercaptoethanol and heated at 95oC for 
15 minutes. The samples were ran at 125 V for 60 min in 25 mM Tris, 192 mM glycine, 
1. 0% SDS, pH 8. 3 running buffer. Prior to running the native samples the 4-20% tris-
HCl gel was run in 25 mM tris, 192 mM glycine, pH 8. 3 native running buffer for 60 min 
to remove the SDS from the gel. Samples prepared for the native gel were buffer 
exchanged into 20 mM tris, 100 mM NaCl, pH 8 buffer and concentrated to 25 µM in 20 
µL using Amicon centrifugal filter units with a molecular weight cut-off of 10 kDa. Each 
sample was run individually along with 1:1 mixtures of CopN:CT663 and 
CopN:Scc1/CT663. These mixtures were incubated at 25oC for 1. 5 hr. 10% glycerol 
was added to the native sample in a 1:2 ratio and the native gel was fun for 75 min at 
125 V.  
4. 2. 8 Gel filtration analysis   
CT663 and the Scc1/CT663 complex were analyzed with quantitative gel filtration 
analysis using either a HiPrep Sephacryl S-100 HR with a 1 mL sample injection volume 
or an ENrich 70 SEC column with a 50 µL sample injection volume. Two stock solutions 
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of CT663 and two stock solutions of the Scc1/CT663 complex were prepared for 
analysis using Amicon centrifugal filter units with a molecular weight cut-off of 10 kDa. 
The concentrations and buffer conditions of each sample are listed in Table 4-1. Protein 
concentrations were determined using the Bradford colorimetric assay with Coomassie 
Plus reagent and a Biotek PowerWave XS microplate spectrophotometer. Standard 
curves were generated using molecular weight standards (2 mg/mL BSA, 1 mg/mL β-
lactoglobulin, 1 mg/mL cytochrome C, and 50 mM cytidine) using each running buffer:  
(1) 20 mM tris, 150 mM NaCl, pH 8. 0, (2) 20 mM tris, pH 7. 4, (3) 50 mM potassium 
phosphate monobasic/sodium phosphate dibasic (K-Na-phosphate), pH 7. 3, and (4) 20 
mM sodium acetate, pH 4. 5. Regression analysis was used to determine the linear 
relationship between the elution volume and the logarithm of the molecular weight for 
each column/buffer combination. The molecular weights of the samples were 
determined using the linear function to determine the oligomeric state of the samples in 
each buffer.  
4. 2. 9 SPR Analysis 
Binding experiments were conducted using a kinetic titration method called 
single-cycle kinetics. This method consists of serial injections of analyte at increasing 
concentrations over the surface of a ligand-functionalized sensor chip surface without 
regeneration between sample injections [91]. SPR studies were performed at 25 oC on 
a nitrilotriacetic acid (NTA) chip (Xantec) on a BIAcore T100 system (GE Healthcare). 
Both cells of the uncharged NTA chip were conditioned with 0. 5 M EDTA at a flow rate 
of 10 μL/min with 180 s of contact time, followed by 0. 1 M NaOH at a flow rate of 10 
μL/min with 180 s of contact time. Two capture cycles were performed on the second 
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cell of the sensor chip to create a capture baseline. The capture cycle included three 
steps: charging the surface with Ni2+, capturing the ligand, a series of washes, and 
surface regeneration. The second cell of the chip was charged with 5 mM NiCl2 at a flow 
rate of 10 μL/min with a contact time of 120 s. Charging the surface with nickel allows 
the binding of histidine tagged ligands, such as the His-Scc1/Ct663 complex. The His-
Scc1/CT663 complex was prepared in running buffer (50 mM potassium phosphate, 
150 mM NaCl, 5 mM EDTA, 0. 005 % Tween at pH 7. 3) and immobilized onto the 
surface at a flow rate of 10 μL/min with a contact time of 150 s. The chip was 
regenerated with 0. 5 M NaOH at a flow rate of 30 μL/min for 2 min, followed by 350 mM 
EDTA at 30 μL/min for 2 min. The capture cycle was repeated. The analyte binding step 
was a single cycle kinetic method with 5 increasing concentrations. This cycle consisted 
of a charging step, a ligand capture step, followed by 5 analyte binding and dissociation 
steps. CopN, the analyte, was flown at a rate of 10 μL/min with 150 s of contact time 
across the second cell with a dissociation time of 240 s. The parameters of the other 
steps were the same. CopN was passed across the surface of the first flow cell as a 
control or blank.  
4. 2. 10 NMR buffer optimization for CT663 
CT663 was expressed in minimal media as previously described (Chapter 3). 
Isotopic labeling was incorporated by adding 15NH4Cl to the MM. The proteins were 
purified with Ni-affinity chromatography as previously described. Purified CT663 was 
purified with size exclusion chromatography using a Hiprep 16/60 Sephacryl-S-100 HR 
column in 20 mM PBS at pH 7. 15N-CT663 was concentrated to 500 µM and exchanged 
into 20 mM sodium phosphate, 20 mM tris, and 20 mM MES buffers using Amicon 
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centrifugal filters units with a molecular weight cut-off of 3 kDa. The samples were 
concentrated to a final volume of 250 µL and transferred to 5 mm Shigemi tubes with 
10% D2O. An 1H -15N HSQC spectrum of each sample was collected on a Varian 700 
MHz NMR.  
4. 2. 11 15N-CT663/Scc1 NMR analysis 
15N-CT663 was expressed, purified, exchanged into 20 mM sodium acetate at pH 
6 buffer, and concentrated to 500 µM as previously described. pACYC-184-Scc1 was 
transformed into BL21 cells and selected on LB agar with 35 µg/mL chloramphenicol. A 
single colony was added to 10 mL of LB and grown overnight. This starter culture was 
added to a 1L of LB and cultured at 37 oC until it reached an OD600 of 0.6-0.8. The cells 
were induced with 0. 5 mM IPTG and cultured at 37 oC for 3 hr. The cells were 
harvested by centrifugation at 4000 g for 10 minutes at 4 oC and reconstituted in 10 mL 
of 8 M urea in BugBuster. Sonication at 30% power pulsed for 120 s (3 cycles of 30 s 
on/10 s off) was used to lyse the cells, and cleared lysate was prepared by 
centrifugation at 30,000 g for 30 min at 4 oC. After filtering the cleared lysate with a 0. 
22 µM syringe filter. The denatured Scc1 was bound to Sepharose 6 fast flow media 
using the FLPC. The media was washed with 10 mL of 20 mM sodium phosphate, 300 
mM NaCl, 20 mM imidazole, and 6 M urea at pH 8 buffer. A 30 mL linear gradient at 0. 
1 mL/min from 6 M urea to 0 M urea was used to refold the protein on the column. 
Refolded Scc1 was eluted with 20 mM sodium phosphate, 300 mM NaCl, and 300 mM 
imidazole at pH 8 buffer. Scc1 was exchanged into 20 mM sodium acetate at pH 6 
buffer and added to the 15N-CT663 sample. The 1H -15N HSQC spectra of 250 µL of 500 
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µM 15N-CT663 before and after the addition of Scc1 were collected on a Varian 700 
MHz NMR.  
4. 3 Results 
4. 3. 1 Structural predictions of the Chlamydial trachomatis T3SS effectors-
chaperone complex CT663:SCC1:CopN 
The T3SS is not exclusive to Chlamydia trachomatis and is used by other 
pathogens as well. The T3SS apparatus itself has been shown to display notable 
similarities among different bacterial species [92]. E. coli, Yersinia, Salmonella, and 
Shigella are a few examples of pathogens that use the T3SS. The macromolecules of 
the T3SS are well characterized for these pathogens. High-resolution crystal structures 
of all classes of T3SS chaperones, crystal structures of the proteins involved in basal 
body formation, and NMR and FTIR analyses of needle proteins have advanced the 
structural knowledge of the T3SS [92]. Using the structures of chaperones and effectors 
from other bacterial species as a basis has allowed for a structural prediction of 
CT663/Scc1 in complex with CopN. Protein homology/analogy recognition engine 
version 2. 0 (Phyre2) is a structure prediction server that uses homology/analogy of 
known structures to predict the structure of other proteins. Structural homology is based 
on two principles: “first, the structure of a protein is determined by it’s amino acid 
sequence; second, proteins with similar sequences are practically identical in structure, 
and even proteins that have distantly related sequences still fold into similar structures” 
[93]. Protein analogy refers to proteins with similar functions despite their different 
sequences. The structure of CT663 was predicted with 97% sequence coverage from 4 
template structures of T3SS chaperones from other bacteria [94-97]. The structure of 
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Scc1 was predicted based on three proteins with 92% coverage [94, 97, 98]. The 
structural orientation of CopN in complex with CT663/Scc1 was predicted based on a 
Yeseria pestis effector chaperone complex (PDB 1XKP) [99]. The Yeseria pestis 
complex as well as a protein from Shigella flexneri was used to predict the structure of 
CopN with 92% coverage [99, 100]. The structure prediction was done to better 
understand how CT663 forms a complex with SCC1 and CopN.  
 
Figure 4-3  The CopN:CT663:Scc1 structure is modeled using Yersinia pestis virulence 
factor YopN in complex with the heterodimeric chaperone SycN-YscB by Phyre2.  
4. 3. 2 Expression and Purification  
The expression and purification conditions were optimized by Dr. Li Shen, our 
collaborator at the LSU Health Science Center School of Medicine. CT663, Scc1/Ct663, 
and CopN express with yields of ~5 mg, ~66 mg, and ~2 mg of protein per liter of 
culture, respectively. The purification of these proteins is relatively clean. Figure 4-4 
shows the SDS-PAGE and native gel analysis of the purified proteins. The SDS-PAGE 
gels separate denatured proteins based on their size and charge. While native gels 
separate the proteins in the same manner, the proteins are in their native state and SDS 
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is not available to bind and add negative charge. Without SDS to denature and add 
uniform negative charge, it is hard to determine the exact mass of the native proteins. 
However, it appears that CT663 and CT663/Scc1 form dimers under native conditions. 
CopN was cloned and expressed with a glutathione S-transferase (GST) fusion tag for 
purification. This GST tag forms dimers, so the CopN dimer was expected and not 
informative. While Figure 4-4a shows CopN cleaved from GST, the CopN used for the 
native gel is not cleaved. A quick and dirty binding assay, mixing proteins in 1:1 ratio, 
showed no binding of the chaperones with CopN. This result is inconsistent with gel 
filtration analysis and is likely an artifact from interactions with the gel and/or 
interference from the GST fusion tag.  
 
Figure 4-4   SDS-PAGE and native PAGE analysis of CT663, Scc1/CT663, and CopN. 
The protein molecular weight ladder is shown in lane 1 in the (a) SDS-PAGE and (b) 
native PAGE gel images. The molecular weight of CT663, Scc1/Ct663 and CopN are 
14. 7 kDa, 30. 9 kDa, and 45. 2 kDa respectively.  
4. 3. 3 Separation of CT663/Scc1 complex 
The CT663/Scc1 complex is expressed within E. coli as a complex and also co-
purifies. The fact that CT663 and Scc1 purify together suggests a very low dissociation 
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constant. Since Scc1 is difficult to produce when expressed in E. coli alone, we tried to 
separate CT663 and Scc1 and recover each protein in a soluble, folded state. The 
complex was bound to nickel affinity media through the His-tag on Scc1. Urea was used 
to try to separate and elute CT663 from Scc1. 6 and 8 M urea were not sufficient to 
destabilize the interaction between the CT663 and Scc1. Urea is a very common 
compound used to denature proteins. The exact mechanism of how urea denatures 
proteins is not known, but studies have shown that urea disrupts hydrophobic 
interactions. Urea also interacts with polar residues and the peptide backbone to 
stabilize the denatured form of the protein [101]. The fact that 8 M urea is not enough to 
separate CT663 from Scc1 suggests that interactions other than hydrophobic, like 
electrostatic and hydrogen bonds, contribute to the stability of the complex.  
 
 
Figure 4-5  CT663-Scc1 interaction. Purified CT663 and CT663:Scc1 complex are 
shown in lanes 2 and 3, respectively. The purified CT663-Scc1 complex was 
immobilized on 1 mL of Ni-affinity media via a 6XHis tag on Scc1 and washed with 20 
mL of wash buffer with 6 M urea (lane 4), 8 M urea (lane 5), and 2% SDS (lane 6). Even 
under strong denaturing conditions of 8 M urea, some CT663 remained bound to 6XHis-
tagged Scc1. SDS (2%) was sufficient to disrupt the CT663:Scc1 interaction, resulting in 
pure Scc1.  
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4. 3. 4 Buffer dependent gel filtration analysis 
Gel filtration was done in an effort to characterize the oligomeric state of the 
chaperones CT663 and CT663/Scc1. The goal of this study was to find conditions 
where the chaperones were in their monomeric state. CT663 and Scc1 formed a 
heterodimer in 20 mM sodium acetate at pH 4. 5, while CT663 formed high order 
oligomers regardless of buffer conditions.  
 
Figure 4-6 Gel filtration analysis of CT663 and CT663:Scc1 at various buffer conditions. 
Two gel filtration column were used to analyze the samples: (A) a HiPrep Sephacryl S-
100 HR column using a 1 mL sample volume and (B) an Enrich SEC 70 column using 
50 L sample volumes. Molecular weight standards were used to determine the linear 
relationship between the elution volume and the logarithm of the molecular weight for 
each column/buffer combination. The molecular weight of the samples were determined 
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using the best-fit linear function based on regression analysis to determine the 
oligomeric state of the samples in each buffer. The sample concentrations were 81-152 
µM except for the CT663:Scc1 complex in sodium acetate, which was 27 µM due to its 
instability in this buffer. Details about the sample conditions are described in Table 4-1. 
(A)  In Tris/saline buffer at pH 8. 0, CT663 (solid black line) predominantly exists as 
higher order oligomers (>300 kDa) and as a homodimer while the CT663:Scc1 complex 
(dashed black line) predominantly forms a stable tetramer. In acetate buffer at pH 4. 5, 
CT663 and the CT663:Scc1 complex are unstable. CT663 readily precipitates, but the 
complex stability was better and showed that soluble CT663:Scc1 in acetate buffer 
(gray solid line) exists as a heterodimer. (B)  In phosphate buffer at pH 7. 3 (solid black 
line), CT663 forms a homodimer and in Tris buffer at pH 7. 4 (dashed black line), CT663 
forms homotrimers.  
4. 3. 5 Detergent assisted Gel filtration 
Since different buffers and salt did not separate CT663 oligomers, detergents 
were added in an attempt to stabilize the monomeric form of CT663. When the 
detergents were added to Tris buffer, it increased the aggregation of the protein (Figure 





Figure 4-7 Detergent effects on CT663 oligomerization. (A) CT663 samples were run in 
20 mM Tris, pH 7. 4 buffer (solid black line) with 1 mM SDS (dotted black line), 10 mM 
SDS (dashed black line), and 0. 01% Triton X-100 (dash-dotted black line). The 
predicted elution volumes for CT663 oligomers (+) were calculated using the calibration 
curve (Table 4. 1). The number of monomer units for each oligomer is shown above the 
marker. (B) CT663 samples were run in 50 mM potassium-sodium phosphate, pH 7. 3 
buffer (solid gray line) with 0. 01% Triton X-100 (dotted gray line) and 1% PEG (dashed 
gray line). The predicted elution volumes for CT663 oligomers (+) are shown as in (A). 
Each sample was 50 L of 81 M CT663 in 50 mM K-Na phosphate, pH 7. 3 buffer, 
except for the sample run in 10 mM SDS/Tris buffer. This sample was diluted by a factor 
of 4 with the running buffer to avoid SDS-phosphate precipitation. The absorbance 
values for this sample were multiplied by 4 for direct comparison to the other samples.   
 
Table 4-1 This table summarized the resulting oligomeric state of CT663 and 
Scc1/CT663 complex in different buffer conditions.  
 
Sample 
(uM) Sample Buffer Running Buffer Column/Sample volume Results 
CT663 
(152) 
20 mM sodium phosphate, 
300 mM imidazole, 300 mM 
NaCl, pH 8. 0 
20 mM Tris, 150 mM 
NaCl, pH 8. 0 
HiPrep 
Sephacryl S-100 





20 mM sodium phosphate, 
300 mM imidazole, 300 mM 
NaCl, pH 8. 0 
20 mM Tris, 150 mM 
NaCl, pH 8. 0 
HiPrep 
Sephacryl S-100 




(27) 20 mM sodium acetate, pH 4. 5 20 mM sodium acetate, pH 4. 5 
HiPrep 
Sephacryl S-100 
HR/ 1 mL 
hetero-
dimer 
CT663 (81) 50 mM K-Na-phosphate, pH 7. 3 20 mM Tris, pH 7. 4 Enrich 70 SEC/ 50 uL trimer 
CT663 (81) 50 mM K-Na-phosphate, pH 7. 3 50 mM K-Na-phosphate, pH 7. 3 Enrich 70 SEC/ 50 uL dimer 
CT663 (81) 50 mM K-Na-phosphate, pH 7. 3 1 mM SDS, 20 mM Tris, pH 7. 4 Enrich 70 SEC/ 50 uL apparent pentamer 
CT663 (20) 50 mM K-Na-phosphate, pH 7. 3 10 mM SDS, 20 mM Tris, pH 7. 4 Enrich 70 SEC/ 50 uL apparent pentamer 
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CT663 (81) 50 mM K-Na-phosphate, pH 7. 3 0. 01% Triton X-100, 20 mM Tris, pH 7. 4 Enrich 70 SEC/ 50 uL apparent tetramer 
CT663 (81) 50 mM K-Na-phosphate, pH 7. 3 
0. 01% Triton X-100, 
50 mM K-Na-
phosphate, pH 7. 3 
Enrich 70 SEC/ 
50 uL apparent dimer 
CT663 (81) 50 mM K-Na-phosphate, pH 7. 3 1% PEG, 50 mM K-Na-phosphate, pH 7. 3 Enrich 70 SEC/ 50 uL apparent dimer 
4. 3. 6 SPR analysis of Ct663/Scc1 binding to CopN 
SPR was carried out at varies concentrations of ligand and analyte to optimize 
the experiment. The Scc1/CT663 ligand concentration was 4 nM. The serial analyte 
concentrations used were 2. 5, 5, 10, 20, and 40 nM of CopN. Raw data was collected 
in the form of a sensogram which plots response units (RU) vs time. The spectra 
corresponding to the blanks and the sample are automatically aligned for subtraction. 
The data is first manually processed by selecting which blanks to subtract from the 
sample run. Sharp peaks, artifacts that occur during injection, are removed from the 
resulting spectrum. The BIAevaluation software was used to fit the data to a curve 
based on a 1:1 binding motif. The rate of association and dissociation of the 
Scc1/CT663 complex and CopN is 1. 01 x 105 +/- 0. 02 x 105 1/Ms and 3. 04 x 10-4 +/- 
0. 16 x 10-4 1/s respectively. The equilibrium dissociation constant is 3. 02 +/- 0. 17 nM, 





Figure 4-8 The SPR sensogram corresponding to the binding event between the 
Scc1/CT663 complex and CopN. The calculated Kd=3. 02 +/- 0. 17 nM.  
4. 3. 7 The magical CT663 sample from never never land 
CT663 prepared by our collaborators was sent to us for HSQC analysis. The 
sample was said to have contained 500 µM CT663 without any purification tags and 20 
mM sodium acetate at pH 4. 5. This sample is a good candidate for structural analysis 
because greater than 90% of the peaks are present. The peaks are well dispersed and 
of similar intensity, suggesting that the protein is fold and possibly in monomeric form. 
This spectrum has not been reproducible because the exact conditions were not known. 
There was a lack of communication from all parties involved in producing the sample 
and obtaining the spectrum. Recent meeting have revealed the appropriate conditions 





Figure 4-9 1H-15N HSQC of 15N labeled CT663. Each peak corresponds to an 1H-15N 
bond from the backbone or a side chain of the protein.  
4. 3. 8 NMR buffer optimization for CT663  
NMR conditions are optimized to obtain good data. The buffer conditions and 
protein concentration are varied until an appropriate spectrum is obtained. A good 
HSQC has well resolve peaks of similar intensity, with one peak for every amino acid 
except proline. Peak distribution is also important, as it gives information about the 
folding of the protein. Well disperse peaks are necessary for a structure determination. 
1H-15N HSQC of 15N labeled CT663 in 20 mM sodium phosphate produced peaks that 
were dispersed. However, the peak intensities are not similar and not resolved between 
8-8. 5 ppm. CT663 in 20 mM tris produce less peaks that vary in intensity, that lack 
dispersion. CT663 in 20 mM MES produced peaks that were not dispersed or similar in 
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intensity. Tris is a terrible buffer for CT663 because it does not allow for the detection of 
an adequate number of amide peaks. There are 142 amino acids that compose CT663, 
accounting for the proline residues there should be 139 backbone amide peaks plus 
additional side chain peaks. There are more peaks for samples in MES and phosphate 
buffer; however, less than 90% of the amide peaks accounted. Peak dispersion is also a 
problem, the peaks between 8-8. 5 ppm appear to be overlapping and of different 
intensity. These peaks indicated that the protein may be aggregated or unfolded.  
 
Figure 4-10 1H-15N HSQC of 15N labeled CT663 in 20 mM sodium phosphate, 20 mM 
tris, and 20 mM MES.  
4. 3. 8 15N-CT663:Scc1 NMR analysis 
The nature of the CT663/Scc1 complex formation is not known. In an effort to 
analyze the effect of Scc1 on CT663, unlabeled Scc1 was added to 15N CT663 and the 
1H-15N HSQC was analyzed. Figure 4-11 shows the overlapped 1H-15N HSQC for 15N 
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CT663 and 15N CT663 complexed with Scc1. The spectra show shifts in the amide 
peaks that correspond to changes in the backbone structure. The inset of Figure 4-11 
shows 13 peaks, 9 of which show varying degrees of shift, signifying a local structural 
change.  
 
Figure 4-11 Scc1 perturbs the amide peaks of 15N-CT663. An overlay of 1H-15N HSQC 
spectra of 15N-CT663 (red) and 15N-CT663:Scc1 (blue). The inset illustrates the 
selective shifts of the putative glycine amide peaks upon binding Scc1. Note:  No peaks 
are covered by the inset.  
4. 3. 9 NMR analysis of the CT663/Scc1 complex 
Preliminary NMR data suggested that the Scc1/CT663 complex is a good sample 
for structure determination, even though it is ~37 kDa. 15N-Scc1/CT663 was expressed 
and purified. The sample was given to Abigael Songok, a graduate student in our lab, 
for further analysis. The sample was desalted into 20 mM ammonium acetate at pH 5. 
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5, frozen at -80 oC, and lyophilized. The protein was reconstituted in 20 mM ammonium 
acetate and 10 mM DTT at pH 5. 5 with 10% D2O. The sample was concentrated to 250 
µL and a 1H-15N HSQC spectrum was collected. The spectrum looks great with 95% of 
the amide peaks accounted. The inset of Figure 4-12 shows the peaks are dispersed in 
the zoomed view.  
 
Figure 4-12 1H-15N HSQC of 15N labeled Scc1/CT663. The inset is a zoomed view to 
show the peak dispersion.  
4. 4 Conclusions 
The goal of this research is to analyze the structure and ligand interactions of 
CT663. CT663 forms a tightly associated complex with Scc1 that cannot be disrupted 
with urea. This suggests that hydrophobic interactions play a minor role in keeping the 
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complex intact. A CopN pull down assay performed by Li Shen showed that CopN does 
not bind CT663 or Scc1 independently, but binds the Scc1/CT663 complex. What 
remains unclear is where, spatially, CopN binds the complex. The Phyre2 server 
predicted a linear structure, where CopN is bound mainly to CT663, and CT663 is 
bound to Scc1. This quaternary structure is possible if the binding of CT663 to Scc1 
causes a conformational change of CT663 that is favorable for CopN binding. It is also 
possible that there is an area near the interface of the Scc1/CT663 complex where 
CopN binds to both proteins. The binding kinetics of Scc1/CT663 was analyzed by SPR. 
The interaction between the chaperone complex and CopN is strong bond with a Kd of 
3. 02 +/- 0. 17 nM.  
In order to obtain good data for structural analysis with NMR, proteins need to be 
in their monomeric state or in small (< 25 kDa) multimeric state. The results of the gel 
filtration experiments indicate that CT663 forms a dimer or a higher order oligomer 
depending on the buffer conditions. Stabilizing the CT663 monomer is not 
straightforward. The overlapped peaks in the center of the 1H-15N HSQC of 15N-CT663 
in sodium phosphate and tris support the finding that CT663 is aggregating under these 
conditions. The 1H-15N HSQC of the 15N-CT663 sample sent to us by our collaborators 
showed a very different scenario. The buffer conditions were never replicated because 
the protein we produced precipitated when the pH was lowered to 5. After several 
meetings, it was discovered that the CT663 in the magical sample lacked the His-tag 
used for purification. The His-tag increases the isoelectric point (pI) of CT663 causing it 
to precipitate at pH 5 and may also be the source of the aggregation issues. The CT663 
that is in complex with Scc1 does not have a His-tag, thus sarkosyl was used to 
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separate CT663 from the complex for NMR analysis. Abigael Songok is continuing this 
work. If the NMR spectra of CT663 cannot be replicated using sarkosyl to purify the 
protein, then CT663 without the His-tag can be produced and purified using a 
combination of chromatography methods.  
  
Initial NMR experiments showed that when Scc1 is complexes CT663, there is a 
localized change in the backbone structure of CT663. In order to get a better 
understanding of how the structure of CT663 changes, the structure of the complex will 
be analyzed through complete and mixed isotopic labeling. The 1H-15N HSQC of 15N 
Scc1/CT663 is very promising—it should lead to a full 3D structure of the complex. 
Adding CopN to the isotopically labeled complex may give information, such as the 
residues of CT663 and Scc1 that bind CopN and changes to the CT663:Scc1 structure 
when CopN is bound. Knowledge of the binding, even between the complex and CopN, 
could lead to inhibitors that could be used in conjunction with current therapeutics to 
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Supplementary Figures  
 
 
Supplementary Figure 1. Ni-affinity purified, resolubilized pellet from the expression of 
CREB1-Q2-bZIP (pET-28b-CREB1-Q2-bZIP) without (lane1) and with (lane2) co-
expression of OGT (pET-43. 1-OGT) in E. coli BL21-Gold(DE3) analyzed with (a) 
Coomassie-stained SDS-PAGE and (b) anti-O-GlcNAc MAb CTD 110. 6 western blot. 
HEWL, ovalbumin, and protein ladder are shown in the last three lanes, respectively. 
HEWL acts as a positive control for the western blot because the secondary antibody 
(DyLight 550-conjugate Goat anti-Mouse IgG) binds non-specifically to HEWL. Residual 
HEWL can be seen in lanes 1 and 2 because it was used to lyse the cells in these 
preparations. HEWL was not used to lyse cells in any of the other experiments 
presented in this manuscript because of its interference in western blot analysis. The 
western blot of Q2-bZIP (lanes 1 and 2) demonstrates that OGT is modifying the protein 
with O-GlcNAc, consistent with the analysis of Q2-bZIP in the lectin blot in Figure 2. The 
pellets were resolubilized in 6 M urea, centrifuged at 14,000 g at 4 °C for 30 min. Q2-
bZIP was purified from the supernatant using a Bio-Rad BioLogic DuoFlow 
chromatography system with a 1 mL His-Select Ni-affinity gel column. After loading the 
supernatant, the column was washed with 10 mL of 6 M urea in buffer (50 mM sodium 
phosphate, 300 mM NaCl, pH 8. 0), 30 mL gradient (6 – 0 M urea in buffer) at a flow 
rate of 0. 1 mL/min, 10 mL of buffer, and 10 mL of 300 mM imidazole in buffer.   
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Supplementary Figure 2. The CXC fractions of cleared lysate from a culture of BL21-
Gold(DE3) cells expressing empty pET-28b were analyzed using the MU-GlcNAc well-
plate assay with the β-N-acetylglucosaminidase negative (-) and positive (+) controls. 
The active CXC fractions (#4-16) were combined and used to determine the enzyme 
kinetic parameters and activity towards the glycopeptide. Error bars represent the 
standard deviation of three replicate samples. The positive control intensity was 





Supplementary Figure 3. Velocities of pNP-GlcNAc hydrolysis by E. coli β-N-
acetylglucosaminidase, partially purified with CXC from BL21-Gold(DE3) cleared lysate, 
at varying pNP-GlcNAc concentrations. The velocities (nmoles of nitrophenolate formed 
per mL of fraction/min) were calculated from the absorbance at 405 nm of samples 
measured after 4, 9, and 14 min of reaction time. The curve was fitted to the Michaelis-






Supplementary Figure 4. Full 1H NMR spectra of samples from testing the E. coli β-N-
acetylglucosaminidase activity of CXC fractions towards the synthetic O-GlcNAc-
modified peptide, SVES(β-O-GlcNAc)GSADAK-NH2. Each spectrum was treated 




Supplementary Figure 5. Cleared lysate from cultures of (a) ∆nagZ K12 strain and (b) 
parent K12 strain were separated with CXC and analyzed with the MU-GlcNAc well-
plate assay with the β-N-acetylglucosaminidase positive control (+) and negative control 
(-). Error bars represent the standard deviation of three replicate samples. The positive 




Supplementary Figure 6. Full 1H NMR spectra of samples from testing for E. coli β-N-
acetylglucosaminidase activity in ∆nagZ K12 lysate towards the synthetic O-GlcNAc-
modified peptide, SVES(β-O-GlcNAc)GSADAK-NH2. Each spectrum was treated 
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